Orthomoleculair kennisinstituut
Menu

Q10

Wat is q10?

Co-enzym Q10, kortweg CoQ10 of Q10, is een vetoplosbare verbinding met een chemische structuur die vergelijkbaar is met vitamine K (7000). De “Q10” verwijst naar 10 isoprenoïde eenheden bevestigd aan een chinonring. Het is een vetoplosbare, vitamine-achtige stof die in alle cellen in het lichaam voorkomt. Bij mensen komt co-enzym Q10 het meest voor; in andere soorten domineren co-enzymen Q6, Q7, Q8 en Q9 (7000, 11892, 11894). De hoogste concentraties co-enzym Q10 worden gevonden in het hart, de lever, de nieren en de alvleesklier van mensen (7000). Er zijn twee fysiologische vormen van co-enzym Q10 die ook beschikbaar zijn als supplementen: de geoxideerde vorm (ubiquinone) en de gereduceerde vorm (ubiquinol) (95707).

Wetenschappelijke naam

Ubiquinol, Ubiquinone, Ubidecarenone, Mitoquinone

Wat is q10?

Gebruik

Oraal wordt co-enzym Q10 gebruikt voor co-enzym Q10-tekort, hart- en vaatziekten, congestief hartfalen (CHF), angina, verwijde cardiomyopathie, hypertrofische cardiomyopathie, myocarditis, myocardinfarct (MI), diabetes, diabetische neuropathie, hypertensie, hyperlipidemie, anthracycline cardiotoxiciteit kanker en borstkanker. Het wordt ook oraal gebruikt voor bipolaire stoornis, ziekte van Huntington, ziekte van Parkinson, spierdystrofie, atletische prestaties, chronisch vermoeidheidssyndroom (CVS), ziekte van Lyme, pre-eclampsie, door warfarine veroorzaakt haarverlies, autismespectrumstoornis en aan chemotherapie gerelateerde vermoeidheid . Co-enzym Q10 wordt ook oraal gebruikt voor het stimuleren van het immuunsysteem bij mensen met HIV/AIDS, levensverlenging, mannelijke onvruchtbaarheid, migraine, mitochondriale myelopathieën, polycysteus ovarium syndroom (PCOS), niet-alcoholische leververvetting (NAFLD), gerimpelde huid en statine -geïnduceerde myopathie. Het wordt ook oraal gebruikt voor leeftijdsgebonden maculaire degeneratie (AMD), fibromyalgie, ischemie-reperfusieschade, multiple sclerose (MS), ziekte van Peyronie, ziekte van Alzheimer, amyotrofische laterale sclerose (ALS, ziekte van Lou Gehrig), cocaïneverslaving, post- poliosyndroom, astma, cerebellaire ataxie, chronische obstructieve longziekte (COPD), cyclisch braken syndroom (CVS), droge mond, staar, Friedreich ataxie, gehoorverlies, hepatitis C, door de moeder overgeërfde diabetes mellitus en doofheid (MIDD), Prader-Willi syndroom (PWS) en sepsis.

Plaatselijk wordt co-enzym Q10 gebruikt voor parodontitis. Als een oogdruppel wordt co-enzym Q10 gebruikt voor hoornvlieszweren en droge ogen.

Gebruik

Werking

Co-enzym Q10 is een vitamine-achtige verbinding die aanwezig is in vrijwel alle cellen en in bijzonder hoge concentraties in het hart, de lever, de nieren en de alvleesklier. In de cel wordt 25% tot 30% van het totale co-enzym Q10 in de kern gevonden, 40% tot 50% in de mitochondriën, 15% tot 20% in de microsomen en 5% tot 10% in de cytosol. Co-enzym Q10 is in vet oplosbaar en werkt vergelijkbaar met een vitamine (2134, 11892). Zijn primaire functies omvatten activiteit als een antioxidant, een membraanstabilisator en als een cofactor in veel metabole routes, met name bij de productie van adenosinetrifosfaat (ATP) bij oxidatieve ademhaling (2134, 6037, 6048, 6410, 11892).

Het lichaam produceert voldoende hoeveelheden co-enzym Q10, dus het wordt niet beschouwd als een vitamine (11893). Het wordt ook ingenomen in kleine hoeveelheden uit voedingsbronnen, waaronder vlees en zeevruchten. De hoeveelheden ingenomen in voedingsmiddelen benaderen echter niet de therapeutische doses. Co-enzym Q10 in sojaolie lijkt een superieure biologische beschikbaarheid te hebben in vergelijking met andere formuleringen (457).

De biosynthese van co-enzym Q10 is een 17-stappenproces dat riboflavine, niacinamide, pantotheenzuur (B5), pyridoxine, cobalamine (B12), foliumzuur, vitamine C en andere sporenelementen vereist (89413). Tekorten aan serumco-enzym Q10 kunnen worden veroorzaakt door onvoldoende inname van deze voedingsstoffen.

Werking

Veiligheid

Waarschijnlijk veilig

Indien oraal en op de juiste manier gebruikt. Co-enzym Q10 is veilig gebruikt in onderzoeken die maximaal 5 jaar duren, bij lokaal gebruik op het tandvlees (2107, 2108, 2134, 6037, 6038, 6407, 8163, 8916, 8917, 8918, 8938, 8939, 8940, 15395, 17413, 17716, 96538).

Kinderen

Waarschijnlijk veilig

Wanneer oraal en op de juiste manier gebruikt. Co-enzym Q10 in doses van 1-10 mg/kg/dag is tot 9 maanden veilig gebruikt onder medisch toezicht (12199, 13223, 15256, 44005).

Zwangerschap

Mogelijk veilig

Wanneer oraal en op de juiste manier gebruikt. Co-enzym Q10 100 mg tweemaal daags is met schijnbare veiligheid gebruikt tijdens de zwangerschap, beginnend bij een zwangerschapsduur van 20 weken tot het einde van de zwangerschap (17201).

Lactatie

Onvoldoende betrouwbare informatie beschikbaar; vermijd te gebruiken.

Effectiviteit

Waarschijnlijk effectief

Co-enzym Q10-tekort
Zeldzame gevallen van gedocumenteerde co-enzym Q10-tekort met symptomen van zwakte, vermoeidheid en epileptische aanvallen zijn gemeld. Co-enzym Q10 oraal innemen lijkt de symptomen van een tekort te verbeteren (8160, 8161). Oraal co-enzym Q10 800 mg dagelijks driemaal, is aanbevolen voor de behandeling van co-enzym Q10-tekort bij volwassenen. Bij kinderen is 30 mg/kg per dag in drie verdeelde doses aanbevolen (89417).

Mitochondriale myopathieën
Co-enzym Q10 oraal innemen lijkt de symptomen te verminderen bij sommige patiënten met genetische en verworven aandoeningen van mitochondriale dysfunctie (8159, 8162, 8163, 8912, 11050, 44240, 97905). Het effect begint langzaam, met een maximaal effect na 6 maanden (8163). Een specifieke co-enzym Q10-formulering (UbiQGel, Tishcon Corporation) heeft de Amerikaanse Food and Drug Administration (FDA) weesgeneesmiddelstatus bereikt voor mitochondriale myopathieën, waaronder MELAS (myoclonische epilepsie met lactaatacidose en beroerte-achtige afleveringen) syndroom, Kearns-Sayre-syndroom en MERRF (myoclonus epilepsie met rafelige rode vezels).

Mogelijk effectief

Congestief hartfalen (CHF)
Populatieonderzoek heeft aangetoond dat hartfalen geassocieerd is met lage co-enzym Q10-waarden (44220). Bovendien kunnen co-enzym Q10-waarden een voorspeller zijn van mortaliteit bij patiënten met hartfalen (44059). Sommige klinische onderzoeken tonen aan dat suppletie met co-enzym Q10 gunstig kan zijn voor patiënten met hartfalen. Een analyse van beschikbaar klinisch onderzoek uit 2017 bij patiënten met hartfalen toont aan dat dagelijks gebruik van co-enzym Q10 30-300 mg de inspanningscapaciteit verbetert en de mortaliteit met 31% vermindert in vergelijking met placebo. Co-enzym Q10 is echter niet geassocieerd met een verandering in de ejectiefractie of de classificatie van de New York Heart Association (NYHA) (97902). De grootste studie in deze analyse laat zien dat het dagelijks innemen van co-enzym Q10 300 mg gedurende maximaal 2 jaar de dood of ziekenhuisopname vermindert bij patiënten met NYHA klasse III-IV hartfalen die conventionele therapie krijgen. In deze specifieke populatie is het aantal patiënten dat moet worden behandeld om één groot cardiovasculair voorval te voorkomen 9 (96542). Ander klinisch onderzoek toont aan dat toevoeging van oraal co-enzym Q10 aan conventionele behandelingen de kwaliteit van leven lijkt te verbeteren en symptomen van hartfalen zoals dyspneu, perifeer oedeem, vergrote lever en slapeloosheid bij patiënten met milde tot ernstige (NYHA klasse II-IV) CHF lijkt te verminderen (6407, 6408, 6409, 8909, 12170, 44042, 44288, 44289, 44304, 44334, 44352). Aanvullend klinisch onderzoek toont aan dat het dagelijks innemen van co-enzym Q10 30 mg als adjuvans bij standaardzorg de incidentie van atriumfibrilleren met ongeveer 73% vermindert in vergelijking met standaardzorg (alleen bij patiënten met NYHA klasse II-IV CHF) (95609).

Diabetische neuropathie
Klinisch onderzoek toont aan dat het dagelijks gebruiken van co-enzym Q10 400 mg gedurende 12 weken de parameters van zenuwgeleiding en symptomen van neuropathische pijn en stoornissen aanzienlijk verbetert in vergelijking met placebo bij diabetespatiënten met polyneuropathie (44217).

Fibromyalgie
Klinisch onderzoek toont aan dat het dagelijks innemen van co-enzym Q10 400 mg gedurende 3 maanden de pijn verbetert met 24% tot 37%, vermoeidheid met 22% en slaapstoornissen met 33% in vergelijking met placebo bij vrouwen met fibromyalgie (97913). Voorlopig klinisch onderzoek toont ook aan dat het dagelijks gebruik van co-enzym Q10 300 mg gedurende 40 dagen de pijn met 52% tot 56% vermindert, vermoeidheid met 47%, ochtendmoeheid met 56% en gevoelige punten met 44% in vergelijking met placebo (89416). Deze patiënten ervoeren ook een verbetering van psychische symptomen, waaronder een vermindering van interpersoonlijke gevoeligheid, depressie, angst en vijandigheid (97912).

Co-enzym Q10 is ook geëvalueerd in combinatie met ginkgo (Bio-Biloba, Pharma Nord) voor de behandeling van fibromyalgie. Het dagelijks gebruiken van deze combinatie gedurende 12 weken verbetert de kwaliteit van leven, zoals fysieke fitheid, emotionele gevoelens, sociale activiteiten, algehele gezondheid en pijn in vergelijking met baseline (17716).

HIV/AIDS
Co-enzym Q10 oraal innemen lijkt de immuunfunctie bij patiënten met HIV/AIDS te verbeteren (2123, 2124).

Ischemie-reperfusieletsel
Klinisch onderzoek toont aan dat co-enzym Q10 oraal of intraveneus gedurende een week vóór cardiale bypass of vaatchirurgie hypoxische schade tijdens chirurgie vermindert (11902, 11903, 44031, 44294). Eén klinische studie toont aan dat het dagelijks innemen van co-enzym Q10 300 mg gedurende 2 weken voorafgaand aan cardiale bypass-chirurgie de subjectieve kwaliteit van leven verbetert in vergelijking met placebo na een follow-up van 37 maanden (43937). Sommige klinische onderzoeken wijzen er echter op dat co-enzym Q10 oraal, binnen 24 uur vóór de operatie, of in kleine doses van 100 mg per dag geen effect heeft op de hartfunctie of troponinespiegels in vergelijking met placebo na reperfusiechirurgie (11904, 44292). Co-enzym Q10 in combinatie met magnesium, selenium en omega-3-vetzuren gedurende 2 maanden voorafgaand aan en een maand na hartchirurgie lijkt de troponinespiegels en de duur van ziekenhuisopname aanzienlijk te verminderen (21651).

Migraine
Sommige klinische onderzoeken tonen aan dat orale inname van co-enzym Q10 de frequentie van hoofdpijn met ongeveer 30% en het aantal dagen met hoofdpijngerelateerde misselijkheid met ongeveer 45% verlaagt bij volwassenen (8135, 11872). Een andere studie toont aan dat het dagelijks innemen van co-enzym Q10 (WN Pharmaceuticals, Ltd.) gedurende 3 maanden 100 mg de ernst van migraine, het aantal gemiste werkdagen als gevolg van migraine vermindert en de frequentie met de helft bij 60% van de patiënten (95608). Om de frequentie van migraine bij volwassenen met 50% te verminderen, is het aantal dat nodig is om (NNT) te behandelen met co-enzym Q10 100 mg TID gedurende 3 maanden (11872). Het kan tot 3 maanden duren voor een aanzienlijk voordeel (11872, 95608). In een meta-analyse van 5 onderzoeken verminderde co-enzym Q10 het aantal migraine-aanvallen per maand niet, maar verminderde het de duur van migraine en het aantal dagen met migraine in een maand (99430). Richtlijnen van de American Academy of Neurology beschouwen co-enzym Q10 mogelijk effectief voor de preventie van migraine (99430).

In één observationeel onderzoek is aangetoond dat het nemen van een specifiek combinatieproduct (Antemig, PiLeJe) met co-enzym Q10 100 mg, moederkruid 100 mg, magnesium 112,5 mg en vitamine B6 1,4 mg per dag gedurende 12 weken het aantal hoofdpijndagen per maand vermindert met 3,5 dagen en tegelijkertijd de kwaliteit van leven verbeteren in vergelijking met baseline (96531).

Bij kinderen en adolescenten suggereert klinisch onderzoek dat het gebruik van co-enzym Q10 100 mg gedurende 16 weken de frequentie, ernst of duur van de hoofdpijn niet significant verbetert in vergelijking met placebo (44197). Het gebruik van co-enzym Q10 lijkt echter de migraine-frequentie te verminderen bij kinderen met een laag co-enzym Q10 (15256).

Multiple sclerose (MS)
Klinisch onderzoek toont aan dat het dagelijks innemen van co-enzym Q10 500 mg gedurende 3 maanden vermoeidheid en depressie vermindert bij MS-patiënten (96539).

Spierdystrofie
Co-enzym Q10 oraal innemen lijkt de fysieke prestaties te verbeteren bij sommige patiënten met spierdystrofieën (2127).

Myocardinfarct (MI)
Klinisch onderzoek suggereert dat oraal innemen van co-enzym Q10 het risico op cardiale gebeurtenissen lijkt te verminderen bij patiënten met recent MI die risico lopen op atherotrombose. Wanneer gestart bij patiënten binnen 72 uur na MI, lijkt co-enzym Q10 het risico op cardiale gebeurtenissen, waaronder niet-fatale MI en hartdood, aanzienlijk te verminderen met 52% bij toediening gedurende 28 dagen en met 45% bij toediening gedurende maximaal een jaar (10152, 44330). In één klinisch onderzoek verbeterde het toedienen van een enkele oplaaddosis van 250 mg co-enzym Q10 gevolgd door drie dagelijkse doses van 150 mg via een nasogastrische buis gedurende 5 dagen de overlevingskans van 3 maanden aanzienlijk met 134% vergeleken met placebo bij patiënten met recente MI die reanimatie kreeg (43935).

Sommige klinische onderzoeken tonen aan dat het dagelijks gebruiken van een combinatie van 100 mg co-enzym Q10 en 100 mcg selenium gedurende een jaar, het risico op verlenging van het QT-interval met 60% verlaagt in vergelijking met placebo bij post-MI-patiënten (44275).

Peyronie-ziekte
Klinisch onderzoek toont aan dat bij patiënten met vroege chronische Peyronie-ziekte, het gebruik van co-enzym Q10 (Kaneka Nutrients, Osaka) gedurende 24 weken 300 mg per dag gedurende 24 weken nieuwe plaquevormingen aanzienlijk vermindert en de erectiele functie en plaquegrootte verbetert in vergelijking met placebo. Bovendien hebben patiënten die deze dosis co-enzym Q10 gebruiken een kans van 75,6% om de ziekteprogressie te vertragen in vergelijking met placebo (44180).

Veiligheid

Bijwerkingen

Oraal, co-enzym Q10 wordt over het algemeen goed verdragen. In klinische onderzoeken zijn geen significante bijwerkingen gemeld waaronder één onderzoek met een hoge dosis co-enzym Q10 (dagelijks 2,4 gram) gedurende maximaal 5 jaar  (2134 ,6037, 6038, 6047, 8135, 8938, 8939, 8940, 17201, 17413, 43955, 44131, 44233, 44334, 95606, 95607, 95608, 95610, 96538). Co-enzym Q10 kan echter gastro-intestinale bijwerkingen veroorzaken zoals misselijkheid, braken, diarree, onderdrukking van de eetlust, brandend maagzuur en epigastrisch ongemak, hoewel dit voorkomt bij minder dan 1% van de patiënten (2134, 3370, 6409, 8135, 8938, 8939, 8940, 10152). Sommige van deze bijwerkingen kunnen worden geminimaliseerd als de totale dagelijkse doses van meer dan 100 mg worden verdeeld en twee tot drie keer per dag worden toegediend (3370).

Bijwerkingen

Interacties

Medicijnen

Alkylerende agenten
Theoretisch kunnen antioxidanten zoals co-enzym Q10 tumorcellen beschermen tegen chemotherapeutische middelen die werken door oxidatieve stress te induceren, zoals de alkylerende middelen (bijv. Cyclofosfamide, Cytoxan) en radiotherapie (5158, 5159). Het klinische belang van deze interactie is onbekend en vereist verder onderzoek.

Antihypertensieve drugs
Co-enzym Q10 kan de bloeddruk verlagen en kan additieve bloeddrukverlagende effecten hebben bij gebruik met antihypertensiva; voorzichtig gebruiken. Sommige antihypertensiva omvatten captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), amlodipine (Norvasc), hydrochloorthiazide (HydroDiuril), furosemide (Lasix) en vele anderen (2122, 9890, 17702, 43932, 43982).

Doxorubicin (Adriamycin, anderen)
Voorlopig bewijs suggereert dat de niveaus van co-enzym Q10 zijn verhoogd bij kinderen en adolescenten van 2,5-19 jaar oud met kanker die doxorubicine (Adriamycin) krijgen in vergelijking met andere chemotherapeutica (14412). Dit kan een gevolg zijn van de afgifte van co-enzym Q10 uit apoptotisch hartweefsel. Co-enzym Q10 lijkt de farmacokinetiek van doxorubicine niet significant te veranderen (14413). De invloed van co-enzym Q10 op de effectiviteit van doxorubicine is onbekend.

Warfarin (Coumadin)
Gelijktijdig gebruik kan de antistollingseffecten van warfarine verminderen (2128, 6048, 6199). Co-enzym Q10 is chemisch vergelijkbaar met menaquinon en kan vitamine K-achtige procoagulerende effecten hebben. Vier gevallen van verminderde werkzaamheid van warfarine waarvan wordt gedacht dat deze te wijten zijn aan co-enzym Q10 zijn gemeld (2128, 6048, 11048). Er is echter voorlopig klinisch onderzoek dat suggereert dat co-enzym Q10 de effecten van warfarine mogelijk niet significant vermindert bij patiënten met een stabiele INR (11905). Houd patiënten die warfarine en co-enzym Q10 gebruiken nauwlettend in de gaten. Een dosisaanpassing kan nodig zijn.

Kruiden en supplementen

Acacia
Het combineren van co-enzym Q10 met acaciagom lijkt de absorptie van co-enzym Q10 te beïnvloeden. In farmacokinetisch onderzoek bij dieren en mensen verhoogt emulgerend co-enzym Q10 in acaciagom de absorptie van co-enzym Q10 vergeleken met alleen co-enzym Q10 poeder (44168). Theoretisch kan dit het risico op bijwerkingen verhogen.

Beta-carotene
Co-enzym Q10 kan de serumspiegels van beta-caroteen beïnvloeden. In klinisch onderzoek verhoogde suppletie met co-enzym Q10 de bètacaroteenwaarden (44330). Theoretisch kan dit het risico op bijwerkingen verhogen

Kruiden en supplementen met hypotensieve effecten
Co-enzym Q10 kan de bloeddruk verlagen (2122, 9890, 17702, 43932, 43982). Theoretisch kan het combineren van co-enzym Q10 met andere kruiden of supplementen met hypotensieve effecten het risico op hypotensie verhogen. Sommige van deze kruiden en supplementen zijn andrographis, caseïnepeptiden, kattenklauw, co-enzym Q10, visolie, L-arginine, lycium, brandnetel, theanine en anderen.

Omega-3 vetzuren
Co-enzym Q10-niveaus en omega-3-vetzuren kunnen elkaars positieve werking op lipide en non-lipide parameters bij plaquevorming in de slagaders bevorderen. In klinisch onderzoek verbeterde de combinatie van omega-3-vetzuren met co-enzym Q10 de leverenzym-activiteit, bloeddruk en ontstekingsmarkers (44128).

Rode gist rijst
Theoretisch, aangezien rode gist HMG-CoA-reductaseremmer (“statine”) bestanddelen bevat, kan het de co-enzym Q10-waarden verlagen (512).

Vitamine A
Co-enzym Q10 kan de serumspiegels van vitamine A beïnvloeden. In klinisch onderzoek verhoogde suppletie met co-enzym Q10 de vitamine A-waarden (44330). Theoretisch kan dit het risico op bijwerkingen verhogen die verband houden met vitamine A.

Vitamine C
Co-enzym Q10 kan de serumspiegels van vitamine C beïnvloeden. In klinisch onderzoek verhoogde suppletie met co-enzym Q10 de vitamine C-waarden (44330). Theoretisch kan dit het risico op bijwerkingen verhogen die verband houden met vitamine C.

Vitamine E
Co-enzym Q10 kan de serumspiegels van vitamine E beïnvloeden. In klinisch onderzoek verhoogde suppletie met co-enzym Q10 de vitamine E-waarden (44330). Theoretisch kan dit het risico op bijwerkingen geassocieerd met vitamine E verhogen.

Vitamine K
Co-enzym Q10 is chemisch vergelijkbaar met vitamine K2 (menaquinon) en kan vitamine K-achtige effecten hebben, waaronder antagonisme van warfarine (2128, 6048). Gelijktijdig gebruik van co-enzym Q10 en vitamine K kan additieve effecten veroorzaken en het risico op stolling verhogen bij mensen die anticoagulantia gebruiken.

Voedsel

Geen bijwerkingen bekend.

Lab testen

Prostaatspecifiek antigeen (PSA)
Klinisch bewijs toont aan dat het dagelijks innemen van co-enzym Q10 100 mg gedurende 12 weken PSA-waarden tot 33% verlaagt bij gezonde mannen (89423). Theoretisch kan co-enzym Q10 PSA-niveaus en testresultaten beïnvloeden bij mannen die worden gescreend op prostaatkanker.

Ziektes

Hypotensie, Hypertensie
Co-enzym Q10 kan de bloeddruk verlagen. Het kan additieve effecten hebben met medicijnen die worden gebruikt voor hypertensie; voorzichtig gebruiken (2122, 3365, 9890).

Roken
Het roken van sigaretten put het lichaam van co-enzym Q10 uit (7722).

Chirurgie
Co-enzym Q10 kan de bloeddruk beïnvloeden. Theoretisch kan co-enzym Q10 de bloeddrukcontrole tijdens en na chirurgische ingrepen verstoren. Vertel patiënten om co-enzym Q10 ten minste 2 weken voor electieve chirurgische procedures te stoppen.

Interacties

Dosering

Volwassen

Oraal

  • Algemeen: Er zijn verschillende doses co-enzym Q10 gebruikt. Om bijwerkingen te minimaliseren, worden verdeelde dagelijkse doses co-enzym Q10 over het algemeen aanbevolen wanneer doses hoger zijn dan 100 mg per dag (3370).
  • Leeftijdsgebonden maculaire degeneratie: twee capsules van een specifiek combinatieproduct (Phototrop, Sigma-tau Health Science Ltd.) met acetyl-L-carnitine 100 mg, omega-3-vetzuren 530 mg en co-enzym Q10 10 mg dagelijks gedurende 12 maanden zijn gebruikt (43946).
  • Angina: Co-enzym Q10 60 mg eenmaal daags of 50 mg driemaal daags gedurende 4 weken is gebruikt (2121, 44336).
  • Astma: Co-enzym Q10 (Q-Gel, Tishcon Corporation) 120 mg, vitamine E 400 mg en vitamine C 250 mg per dag in aanvulling op conventionele anti-astmatische therapie gedurende 16 weken is gebruikt (43969).
  • Bipolaire stoornis: Co-enzym Q10 800 mg per dag gedurende 4 weken is gebruikt (95606).
  • Borstkanker: Co-enzym Q10 (Bio-Quinone, Pharma Nord), dagelijks 390 mg (3995).
  • Kanker: co-enzym Q10 300 mg, samen met vitamine C 5,7 mg, vitamine E 1,625 mg, selenomethionine 487 mcg, foliumzuur 5 mg, vitamine A 25.000 IE en bètacaroteen 76 mg, allemaal dagelijks in twee verdeelde doses gebruikt (44159).
  • Hart- en vaatziekten (CVD): een combinatie van co-enzym Q10 (Bio-Quinon, Pharma Nord, Denemarken) 100 mg tweemaal daags plus organische seleniumgisttabletten (SelenoPrecise, Pharma Nord) 200 mcg dagelijks gedurende maximaal 5 jaar is gebruikt (92904).
  • Cerebellaire ataxie: Co-enzym Q10 30 mg/kg dagelijks gedurende 2 jaar is gebruikt (44177).
  • Chronische obstructieve longziekte (COPD): Co-enzym Q10 90 mg per dag gedurende 8 weken is gebruikt (44293).
  • Co-enzym Q10-tekort: 150-2400 mg per dag in maximaal drie verdeelde doses is gebruikt (8160, 89417).
  • Congestief hartfalen (CHF): Co-enzym Q10 100 mg per dag verdeeld in twee of drie doses gedurende maximaal 2 jaar of 2 mg/kg dagelijks gedurende maximaal één jaar is in de meeste onderzoeken gebruikt (6037, 6038, 6407, 6408, 6409, 8909, 44288). Er zijn ook voordelen gevonden met lagere doses van 30 mg per dag gedurende 1 jaar of 50-60 mg per dag gedurende maximaal 3 maanden, evenals hogere doses (50-100 mg driemaal daags voor maximaal 2 jaar) (12170, 43967, 43971, 44277, 44289, 44304, 44334, 95610, 96542).
  • Cyclisch braken syndroom (CVS): Co-enzym Q10 10 mg/kg tweemaal daags is gebruikt (17703).
  • Diabetische neuropathie: co-enzym Q10 400 mg per dag gedurende 12 weken is gebruikt (44217).
  • Droge mond: er is gedurende één maand dagelijks 100 mg co-enzym Q10 (ubiquinol) of geoxideerd co-enzym Q10 (ubiquinon) 100 mg gebruikt (44191).
  • Fibromyalgie: Co-enzym Q10 300 mg per dag gedurende 40 dagen is gebruikt (89416, 97912). Co-enzym Q10 200 mg tweemaal daags gedurende 3 maanden is gebruikt (97913). Co-enzym Q10 (Bio-Quinon Q10, Pharma Nord) 200 mg in combinatie met ginkgo (Bio-Biloba, Pharma Nord) 200 mg dagelijks gedurende 84 dagen is gebruikt (17716).
  • Friedreich ataxia: Co-enzym Q10 (Bio-Quinon Q10, Pharma Nord) 200 mg tweemaal daags plus vitamine E (Bio-E-Vitamine, Pharma Nord) 1050 IE tweemaal daags gedurende 2 jaar is gebruikt (43943, 44064).
  • Gehoorverlies: Co-enzym Q10 terclatrate (Qter) 160 mg per dag gedurende 30 dagen is gebruikt (44171, 44184).
  • HIV/AIDS: Co-enzym Q10 100-200 mg per dag is tot 4 jaar en 10 maanden gebruikt (2123, 2124).
  • Hypertensie: Co-enzym Q10 100-200 mg in één tot drie verdeelde doses per dag gedurende maximaal 12 weken is gebruikt (2122, 9890, 17702, 17650, 17651, 44343, 95607). Ook is een specifiek co-enzym Q10-product (Q-Gel, Tishcon Corporation) 60 mg tweemaal daags gedurende 8 weken gebruikt (3365). Voor geïsoleerde systolische hypertensie is co-enzym Q10 60 mg tweemaal daags gedurende 12 weken gebruikt (8907).
  • Hyperlipidemie: Co-enzym Q10 200 mg per dag in combinatie met een omega-3-vetzuursupplement (ZENNIX, Pharma Nord) met docosahexaeenzuur 520 mg en eicosapentaeenzuur 155 mg driemaal daags gedurende 12 weken is gebruikt in combinatie met statine-therapie (97910).
  • Hypertrofische cardiomyopathie: een specifiek co-enzym Q10-product (co-enzym Q10, Vitaline) 120-240 mg per dag totdat de co-enzym Q10-waarden hoger waren dan 2 mcg/ml (11031).
  • Ischemie-reperfusieschade: co-enzym Q10 150-300 mg per dag in maximaal drie verdeelde doses gedurende 1-2 weken voor een operatie is gebruikt om ischemie-reperfusieschade te voorkomen (11902, 11903, 44294). Ook co-enzym Q10 100 mg driemaal daags, magnesiumorotaat 400 mg driemaal daags, liponzuur 100 mg driemaal daags, omega-3 vetzuren 300 mg driemaal daags, en selenium 200 mcg eenmaal daags gedurende ongeveer 2 maanden vóór de operatie en één maand na de operatie (21651).
  • Mannelijke onvruchtbaarheid: co-enzym Q10 200-300 mg per dag gedurende 26 maanden is gebruikt (12169, 17413).
  • Maternaal overgeërfde diabetes mellitus en doofheid (MIDD): co-enzym Q10 150 mg dagelijks gedurende 3 jaar is gebruikt (2125).
  • Migraine hoofdpijn: co-enzym Q10 100 mg één of drie keer per dag of 150 mg eenmaal daags gedurende 3 maanden (8135, 11872, 95608). Vloeibare gelformuleringen van co-enzym Q10 1-3 mg/kg per dag gedurende ongeveer 3 maanden zijn gebruikt bij jonge volwassenen van 22 jaar of jonger (15256).
  • Mitochondriale myopathieën: co-enzym Q10 150-160 mg of 2 mg/kg per dag is gebruikt (8159, 8162, 8163, 44240). In sommige gevallen zijn de doses geleidelijk verhoogd tot 3000 mg per dag (8912).
  • Spierdystrofie: co-enzym Q10 100 mg per dag gedurende 3 maanden is gebruikt (2127).
  • Multiple sclerose (MS): Co-enzym Q10 500 mg tweemaal daags gedurende 3 maanden is gebruikt (96539).
  • Myocardinfarct (MI): Co-enzym Q10 60 mg tweemaal daags gedurende maximaal één jaar is gebruikt (10152, 44330). Ook is vloeibaar co-enzym Q10 (Sanomit, MSE Pharma) 250 mg toegediend als oplaaddosis, gevolgd door vloeibaar co-enzym Q10 (Sanomit, MSE Pharma) 150 mg driemaal daags 150 mg via een nasogastrische buis gedurende 5 dagen (43935). Bovendien is een combinatie van co-enzym Q10 (Bio-Quinon, Pharma Nord), 100 mg plus selenium (Bio-Selenium, Pharma Nord), 100 mcg dagelijks gedurende één jaar gebruikt (44275).
  • Myocarditis: gedurende 2 weken is een niet-gespecificeerde dosis co-enzym Q10 met trimetazidine gebruikt, een anti-angina medicijn dat in China wordt gebruikt (97916).
  • Niet-alcoholische leververvetting (NAFLD): Co-enzym Q10 100 mg per dag gedurende 12 weken is gebruikt (97907).
  • Ziekte van Parkinson: 300 mg, 600 mg, 1200 mg en 2400 mg per dag in 3-4 verdeelde doses per dag gedurende maximaal 24 maanden (8938, 15255, 44212, 95610).
  • Parodontitis: Co-enzym Q10 50 mg per dag gedurende 3 weken is gebruikt (8917,8918).
  • Ziekte van Peyronie: Co-enzym Q10 (Kaneka Nutrients) 300 mg per dag gedurende 24 weken is gebruikt (44180).
  • Polycysteus ovarium syndroom (PCOS): Co-enzym Q10 (Nature Made) 100 mg per dag gedurende 12 weken is gebruikt (97914).
  • Pre-eclampsie: een specifiek co-enzym Q10-product (Q-absorberen, Jarrow Formulas) 100 mg tweemaal daags beginnend bij 20 weken zwangerschap en doorlopend tot het einde van de termijn is gebruikt (17201).
  • Nierfalen: Co-enzym Q10 180 mg dagelijks gedurende 28 dagen is gebruikt (44347).
  • Door statines geïnduceerde myopathie: co-enzym Q10 100 mg per dag gedurende 30 dagen is gebruikt (16008, 44345, 95602). Een hogere dosis co-enzym Q10 100 mg tweemaal daags is gebruikt voor door vlekken geïnduceerde rabdomyolyse (95605).
  • Door Warfarine geïnduceerd haarverlies: Co-enzym Q10 30 mg per dag gedurende maximaal 2 maanden is gebruikt (455).

Topisch

  • Corneale ulceratie: een specifieke oogdruppel (Visudrop, Liba Laboratories) met co-enzym Q10, vitamine E en hypromellose, 2-4 keer per dag toegediend als 1 druppel in het aangedane oog (97904).
  • Droge ogen: een specifieke oogdruppel (VisuXL, Visufarma) met co-enzym Q10 en verknoopt hyaluronzuur in een 1: 1-concentratie, gegeven als 1 druppel in elk oog gedurende 12 weken gedurende 12 weken, is gebruikt (97909).
  • Cataract: een oogdruppeloplossing met co-enzym Q10 plus vitamine E D-alfa-tocoferylpolyethyleenglycol 1000 succinaat, tweemaal daags gedurende 9 maanden is gebruikt (44228).
  • Gerimpelde huid: Crème met 1% co-enzym Q10, tweemaal daags aangebracht gedurende 5 maanden, is gebruikt (44082).
  • Ischemie-reperfusieschade: Intraveneus co-enzym Q10 5 mg/kg twee uur voorafgaand aan cardiale bypass of vasculaire chirurgie is gebruikt (44031).

Kinderen

Oraal

  • Anthracycline-cardiotoxiciteit: co-enzym Q10 100 mg tweemaal daags is gebruikt bij kinderen van 3-12 jaar (44279).
  • Autismespectrumstoornis: een gereduceerde vorm van co-enzym Q10 genaamd ubiquinol (Li-QH, Tishcon Corporation) 50 mg per dag gedurende één week gevolgd door 50 mg tweemaal daags gedurende 11 extra weken is gebruikt (89419).
  • Co-enzym Q10-tekort: co-enzym Q10 60-250 mg per dag in maximaal drie verdeelde doses is gebruikt (8161, 89417).
  • Cyclisch braken syndroom (CVS): co-enzym Q10 10 mg/kg tweemaal daags is gebruikt (17703).
  • Gedilateerde cardiomyopathie: co-enzym Q10 3 mg/kg/dag en 10 mg/kg/dag in 2-3 verdeelde doses gedurende maximaal 9 maanden zijn gebruikt (12199, 13223). Een specifiek vloeibaar preparaat (QuinoMit Q10 Fluid, MSE Pharmazeutika GmbH, Duitsland) 10 mg/kg/dag gedurende 24 weken is ook gebruikt (99427).
  • Migraine-hoofdpijn: vloeibare gelformuleringen van co-enzym Q10 1-3 mg/kg per dag gedurende ongeveer 3 maanden is gebruikt bij pediatrische en adolescente patiënten van 3-22 jaar (15256).
  • Spierdystrofie: co-enzym Q10 100 mg per dag gedurende 3 maanden is gebruikt bij pediatrische en adolescente patiënten in de leeftijd van 8-15 jaar (2127).
  • Prader-Willi-syndroom (PWS): Co-enzym Q10 2,5 mg/kg per dag gedurende één jaar is gebruikt (44005).
Dosering
Referenties
  • 1Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
  • 2Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
  • 3Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994.
  • 4Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
  • 5Foster S, Tyler VE. Tyler’s Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.
  • 6The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  • 31Tang G, Serfaty-Lacrosniere C, Camilo ME, et al. Gastric acidity influences the blood response to a beta-carotene dose in humans. Am J Clin Nutr 1996;64:622-6. View abstract.
  • 45Shanmugasundaram ER, Rajeswari G, Baskaran K, et al. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol 1990;30:281-94. View abstract.
  • 60Bitensky L, Hart JP, Catterall A, et al. Circulating vitamin K levels in patients with fractures. J Bone Joint Surg Br 1988;70:663-4. View abstract.
  • 81Naylor CD, O’Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989;97:1033-42. View abstract.
  • 82Fabbri A, Magrini N, Bianchi G, et al. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr 1996;20:159-64.
  • 83Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111:761-72.
  • 455Nagao T, Ibayashi S, Fujii K, et al. Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 1995;346:1104-5.
  • 456Henriksen JE, Andersen CB, Hother-Nielsen O, et al. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med 1999;16:312-8.
  • 457Weis M, Mortensen SA, Rassing MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994;15:s273-80.
  • 492Eriksson JG, Forsen TJ, Mortensen SA, Rohde M. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999;9:315-8.
  • 512Robbers JE, Tyler VE. Tyler’s Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York, NY: The Haworth Herbal Press, 1999.
  • 1357Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 tolerability in Huntington’s disease. Mov Disord 1996;11:321-3.
  • 2107Hanioka T, Tanaka M, Ojima M, et al. Effect of topical application of coenzyme Q10 on adult periodontitis. Molec Aspects Med 1994;15:S241-8.
  • 2108Watts TLP. Coenzyme Q10 and periodontal treatment: is there any beneficial effect? Br Dent J 1995;178:209-13.
  • 2109Malm C, Svensson M, Ekblom B, et al. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol Scand 1997;161:379-84.
  • 2110Weston SB, Zhou S, Weatherby RP, Robson SJ. Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes? Int J Sport Nutr 1997;7:197-206.
  • 2121Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247-51.
  • 2122Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994;S265-72.
  • 2123Folkers K, Hanioka T, Xia LJ, et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 1991;176:786-91.
  • 2124Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment. Biochem Biophys Res Commun 1988;153:888-96.
  • 2125Suzuki S, Hinokio Y, Ohtomo M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 1998;41:584-8.
  • 2126Andersen CB, Henriksen JE, Hother-Nielsen O, et al. The effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus. Mol Aspects Med 1997;18 Suppl:S307-9.
  • 2127Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochem Biophys Acta 1995;1271:281-6.
  • 2128Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;334:1372-3.
  • 2134Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608.
  • 2135Lewin A, Lavon H. The effect of coenzyme Q10 on sperm motility and function. Mol Aspects Med 1997;18 Suppl:S213-9.
  • 3365Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999;13:203-8.
  • 3366Rotig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000;356:391-5.
  • 3367Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-6.
  • 3368Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine. XV. Inhibition of coenzyme Q10 enzymes by clinically used adrenergic blockers of B-receptors. Res Commun Chem Pathol Pharmacol 1977;17:157-64.
  • 3369Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10 enzymes by clinically used anti-hypertensive drugs. Res Commun Chem Pathol Pharmacol 1975;12:533-40.
  • 3370Fuke C, Krikorian SA, Couris RR. Coenzyme Q10: A review of essential functions and clinical trials. US Pharm 2000;25:28-41.
  • 3653Bertelli A, Ronca G. Carnitine and coenzyme Q10: biochemical properties and functions, synergism and complementary action. Int J Tissue React 1990;12:183-6.
  • 3993Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172-7.
  • 3995Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994;199:1504-8.
  • 4404Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4.
  • 4405Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18:S137-44.
  • 4406Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9.
  • 4407De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA Reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-7.
  • 4408Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994;15:187-93.
  • 4409Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-7.
  • 4410Hanaki Y, Sugiyama S, Ozawa T, et al. Coenzyme Q10 and coronary artery disease. Clin Investig 1993;71:112-5.
  • 4479Kishi T, Kishi H, Watanabe T, et al. Bioenergetics in clinical medicine. XI. Studies on coenzyme Q and diabetes mellitus. J Med 1976;7:307-21.
  • 4846Jolliet P, Simon N, Barre J, et al. Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 1998;36:506-9.
  • 5090Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636-40.
  • 5158Portakal O, Ozkaya O, Erden Inal M, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33:279-84.
  • 5159Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha) 1998;43:505-6.
  • 5248Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 1992;56:95-9.
  • 6037Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549-52.
  • 6038Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1528-33.
  • 6047Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990;65:521-3.
  • 6048Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7.
  • 6199Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160:3226-7.
  • 6407Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term, multicenter, randomized study. Clin Investig 1993;71:S134-6.
  • 6408Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive treatment of congestive heart failure. J Card Fail 1995;1:101-7.
  • 6409Baggio E, Gandini R, Plauncher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994;15 Suppl:S287-94.
  • 6410Pizzorno JE, Murray MT, eds. Textbook of Natural Medicine. 2nd ed. New York: Churchill Livingston, 1999.
  • 7000Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608.
  • 7722Elsayed NM, Bendich A. Dietary antioxidants: potential effects on oxidative products in cigarette smoke. Nutr Res 2001;21:551-67.
  • 8135Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-41.
  • 8159Chan A, Reichmann H, Kogel A, et al. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245:681-5.
  • 8160Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48:1238-43.
  • 8161Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci 1998;156:41-6.
  • 8162Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997;37:212-8.
  • 8163Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990;100:70-8.
  • 8907Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001;94:1112-7.
  • 8908Lonnrot K, Porsti I, Alho H, et al. Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. Br J Pharmacol 1998;124:1500-6.
  • 8909Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997;18:S159-68.
  • 8911Bonetti A, Solito F, Carmosino G, et al. Effect of ubidecarenone oral treatment on aerobic power in middle-aged trained subjects. J Sports Med Phys Fitness 2000;40:51-7.
  • 8912Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001;56:849-55.
  • 8913Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001;20:591-8.
  • 8914de Rijke YB, Bredie SJ, Demacker PN, et al. The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997;17:127-33.
  • 8915Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001;142:E2.
  • 8916Iwamoto Y, Nakamura R, Folkers K, Morrison RF. Study of periodontal disease and coenzyme Q. Res Commun Chem Pathol Pharmacol 1975;11:265-71.
  • 8917Wilkinson EG, Arnold RM, Folkers K, et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol 1975;12:111-23.
  • 8918Wilkinson EG, Arnold RM, Folkers K. Bioenergetics in clinical medicine. VI. Adjunctive treatment of periodontal disease with coenzyme Q10. Res Commun Chem Pathol Pharmacol 1976;14:715-9.
  • 8938Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.
  • 8939Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998;50:793-5.
  • 8940The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001;57:397-404.
  • 8941Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci 2002;22:1592-9..
  • 8958Pepping J. Coenzyme Q10. Am J Health-Syst Pharm 1999;56:519-21.
  • 8959Kishi T, Makino K, Okamoto T, et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q. In: Yamamura Y, Folkers K, Ito Y (eds). Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier/North-Holland Biomedical Press 1980;2:139-54.
  • 9603Bertelli A, Cerrati A, Giovannini L, et al. Protective action of L-carnitine and coenzyme Q10 against hepatic triglyceride infiltration induced by hyperbaric oxygen and ethanol. Drugs Exp Clin Res 1993;19:65-8..
  • 9890Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002;56:1137-42.
  • 10152Singh RB, Neki NS, Kartikey K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003;246:75-82.
  • 11031Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997;18 Suppl:S145-51.
  • 11048Porterfield LM. Why did the response to warfarin change? RN 2000;63:107.
  • 11049Joshi SS, Sawant SV, Shedge A, Halpner AD. Comparative bioavailability of two novel coenzyme Q10 preparations in humans. Int J Clin Pharmacol Ther 2003;41:42-8.
  • 11050Berbel-Garcia A, Barbera-Farre JR, Etessam JP, ET AL. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004;27:187-91.
  • 11416Lerman-Sagie T, Rustin P, Lev D, et al. Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone. J Inherit Metab Dis 2001;24:28-34.
  • 11421Weyer G, Babej-Dolle RM, Hadler D, et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 1997;36:73-82. .
  • 11427Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm 1998;54:301-10.
  • 11872Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64:713-5.
  • 11873FDA. List of Orphan Designations and Approvals. http://www.fda.gov/orphan/DESIGNAT/list.htm (Accessed 19 June 2004).
  • 11877Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003;168:169-79.
  • 11892Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004;1660:171-99.
  • 11893American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 2003;9:417-70.
  • 11894Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001;21:797-806.
  • 11895Ishii N, Senoo-Matsuda N, Miyake K, et al. Coenzyme Q10 can prolong C. elegans lifespan by lowering oxidative stress. Mech Ageing Dev 2004;125:41-6.
  • 11896Lee CK, Pugh TD, Klopp RG, et al. The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice. Free Radic Biol Med 2004;36:1043-57.
  • 11897Welch KM. Current opinions in headache pathogenesis: introduction and synthesis. Curr Opin Neurol 1998;11:193-7.
  • 11898Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
  • 11899Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91.
  • 11900Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001;19:81-3.
  • 11902Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. J Cardiovasc Surg (Torino) 1996;37:229-35.
  • 11903Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 1994;58:1427-32.
  • 11904Taggart DP, Jenkins M, Hooper J, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg 1996;61:829-33.
  • 11905Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost 2002;87:1075-6.
  • 12099Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004;61:889-92..
  • 12169Balercia G, Mosca F, Mantero F, et al. Coenzyme Q10 supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril 2004;81:93-8.
  • 12170Berman M, Erman A, Ben-Gal T, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol 2004;27:295–9.
  • 12199Elshershari H, Ozer S, Ozkutlu S, Ozme S. Potential usefulness of coenzyme Q10 in the treatment of idiopathic dilated cardiomyopathy in children. Int J Cardiol 2003;88:101-2.
  • 13223Soongswang J, Sangtawesin C, Durongpisitkul K, et al. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiol 2005;26:361-6.
  • 14412Eaton S, Skinner R, Hale JP, et al. Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 2000;302:1-9.
  • 14413Zhou Q, Chowbay B. Effect of coenzyme Q10 on the disposition of doxorubicin in rats. Eur J Drug Metab Pharmacokinet 2002;27:185-92.
  • 15115Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006;29:703-12.
  • 15255The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8.
  • 15256Hershey AD, Powers SW, Vockell AB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent Migraine. Headache 2007;47:73-80.
  • 15395Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 2007;64:938-44.
  • 16008Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99:1409-12.
  • 16009Marcoff L, Thompson, PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7.
  • 17201Teran E, Hernandez I, Nieto B, et al. Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia. Int J Gynaecol Obstet 2009;105:43-5.
  • 17413Safarinejad MR. Efficacy of coenzyme Q-10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol 2009;182:237-48.
  • 17650Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994;15 Suppl:s257-63.
  • 17651Yamagami T, Takagi M, Akagami H, et al. Effect of coenzyme Q10 on essential hypertension, a double blind controlled study. In: Folkers KA, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5. Amsterdam: Elsevier Science Publications, 1986:337-43.
  • 17702Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension (review). Cochrane Database Syst Rev 2009;(4):CD007435.
  • 17703Boles RG, Lovett-Barr MR, Preston A, et al. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol 2010;10:10.
  • 17704Lee YJ, Cho WJ, Kim JK, Lee DC. Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. J Med Food 2011;14:386-90.
  • 17705Cordero MD, Moreno-Fernandez AM, deMiguel M, et al. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia. Clin Biochem 2009;42:732-5.
  • 17716Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res 2002;30:195-9.
  • 19206Galasko D. R., Peskind E., Clark C. M., Quinn J. F., Ringman J. M., Jicha G. A., Cotman C., Cottrell B., Montine T. J., Thomas R. G., Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012;69(7):836-841.
  • 21651Leong J. Y., van der Merwe J., Pepe S., Bailey M., Perkins A., Lymbury R., Esmore D., Marasco S., Rosenfeldt F. Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: a randomised trial. Heart Lung Circ 2010;19(10):584-591.
  • 30889Palacka, P., Kucharska, J., Murin, J., Dostalova, K., Okkelova, A., Cizova, M., Waczulikova, I., Moricova, S., and Gvozdjakova, A. Complementary therapy in diabetic patients with chronic complications: a pilot study. Bratisl.Lek.Listy 2010;111(4):205-211.
  • 30915Pfeffer, G., Majamaa, K., Turnbull, D. M., Thorburn, D., and Chinnery, P. F. Treatment for mitochondrial disorders. Cochrane Database.Syst.Rev. 2012;4:CD004426.
  • 34283Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., and Rosano, G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv.Ther 2011;28(12):1105-1113.
  • 37528Schiapparelli, P., Allais, G., Castagnoli, Gabellari, I, Rolando, S., Terzi, M. G., and Benedetto, C. Non-pharmacological approach to migraine prophylaxis: part II. Neurol.Sci. 2010;31 Suppl 1:S137-S139.
  • 37534Mauskop, A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap.Minn.) 2012;18(4):796-806.
  • 42069Nahas, R. Complementary and alternative medicine approaches to blood pressure reduction: An evidence-based review. Can.Fam.Physician 2008;54(11):1529-1533.
  • 43894Abe, K., Matsuo, Y., Kadekawa, J., Inoue, S., and Yanagihara, T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J Neurol.Sci. 1-1-1999;162(1):65-68.
  • 43895Barbiroli, B., Iotti, S., Cortelli, P., Martinelli, P., Lodi, R., Carelli, V., and Montagna, P. Low brain intracellular free magnesium in mitochondrial cytopathies. J Cereb.Blood Flow Metab 1999;19(5):528-532.
  • 43896Nielsen, A. N., Mizuno, M., Ratkevicius, A., Mohr, T., Rohde, M., Mortensen, S. A., and Quistorff, B. No effect of antioxidant supplementation in triathletes on maximal oxygen uptake, 31P-NMRS detected muscle energy metabolism and muscle fatigue. Int J Sports Med 1999;20(3):154-158.
  • 43897Blatt, T., Mundt, C., Mummert, C., Maksiuk, T., Wolber, R., Keyhani, R., Schreiner, V., Hoppe, U., Schachtschabel, D. O., and Stab, F. [Modulation of oxidative stresses in human aging skin]. Z.Gerontol.Geriatr. 1999;32(2):83-88.
  • 43898Zhou, M., Zhi, Q., Tang, Y., Yu, D., and Han, J. Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. J Cardiovasc.Surg.(Torino) 1999;40(3):355-361.
  • 43900Tomasetti, M., Alleva, R., Solenghi, M. D., and Littarru, G. P. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors 1999;9(2-4):231-240.
  • 43901Barbiroli, B., Iotti, S., and Lodi, R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. Biofactors 1999;9(2-4):253-260.
  • 43902Shults, C. W., Haas, R. H., and Beal, M. F. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s disease. Biofactors 1999;9(2-4):267-272.
  • 43903Langsjoen, P. H. and Langsjoen, A. M. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999;9(2-4):273-284.
  • 43904Munkholm H., Hansen H. H., Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors 1999;9:285-9.
  • 43905Sacher, H. L., Sacher, M. L., Landau, S. W., Kersten, R., Dooley, F., Sacher, A., Sacher, M., Dietrick, K., and Ichkhan, K. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. Am J Ther 1997;4(2-3):66-72.
  • 43906Kogan, A. K., Syrkin, A. L., Drinitsina, S. V., and Kokanova, I. V. [The antioxidant protection of the heart by coenzyme Q10 in stable stenocardia of effort]. Patol.Fiziol.Eksp.Ter. 1999;4(4):16-19.
  • 43909Sinatra, S. T. Coenzyme Q10 and congestive heart failure. Ann.Intern.Med 11-7-2000;133(9):745-746.
  • 43910Gottlieb, S. S., Khatta, M., and Fisher, M. L. Coenzyme Q10 and Congestive Heart Failure. Ann.Intern.Med 11-7-2000;133(9):745-746.
  • 43911Del Mar, C. B., Glasziou, P. P., Spinks, A. B., and Sanders, S. L. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 4-16-2001;174(8):421.
  • 43912Lodi, R., Hart, P. E., Rajagopalan, B., Taylor, D. J., Crilley, J. G., Bradley, J. L., Blamire, A. M., Manners, D., Styles, P., Schapira, A. H., and Cooper, J. M. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann.Neurol. 2001;49(5):590-596.
  • 43913Gazdikova, K., Gvozdjakova, A., Kucharska, J., Spustova, V., Braunova, Z., and Dzurik, R. [Effect of coenzyme Q10 in patients with kidney diseases]. Cas.Lek.Cesk. 5-24-2001;140(10):307-310.
  • 43914Strong, M. J. and Pattee, G. L. Creatine and coenzyme Q10 in the treatment of ALS. Amyotroph.Lateral.Scler.Other Motor Neuron Disord 2000;1(suppl 4):17-20.
  • 43915Yamagami, T., Shibata, N., and Folkers, K. Bioenergetics in clinical medicine. Studies on coenzyme Q10 and essential hypertension. Res Commun Chem Pathol.Pharmacol 1975;11(2):273-288.
  • 43916Watson, P. S., Scalia, G. M., Gaibraith, A. J., Burstow, D. J., Aroney, C. N., and Bett, J. H. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 10-15-2001;175(8):447-448.
  • 43917Vitetta, L., Sali, A., and Reavley, N. J. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 10-15-2001;175(8):447-448.
  • 43918Gutzmann, H., Kuhl, K. P., Hadler, D., and Rapp, M. A. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002;35(1):12-18.
  • 43920Rosenfeldt, F. L., Pepe, S., Linnane, A., Nagley, P., Rowland, M., Ou, R., Marasco, S., and Lyon, W. The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium. Biogerontology. 2002;3(1-2):37-40.
  • 43922Jeejeebhoy, F., Keith, M., Freeman, M., Barr, A., McCall, M., Kurian, R., Mazer, D., and Errett, L. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 2002;143(6):1092-1100.
  • 43924Muller, T., Buttner, T., Gholipour, A. F., and Kuhn, W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci.Lett. 5-8-2003;341(3):201-204.
  • 43925Singh, R. B., Kartikey, K., Charu, A. S., Niaz, M. A., and Schaffer, S. Effect of taurine and coenzyme Q10 in patients with acute myocardial infarction. Adv.Exp.Med.Biol. 2003;526:41-48.
  • 43927Snider, I. P., Bazzarre, T. L., Murdoch, S. D., and Goldfarb, A. Effects of coenzyme athletic performance system as an ergogenic aid on endurance performance to exhaustion. Int J Sport Nutr 1992;2(3):272-286.
  • 43928Disdier, P., Harle, J. R., Figarella-Branger, D., Cherif, A. A., Desnuelle, C., and Weiller, P. J. [Ptosis and asthenia manifesting a mitochondrial myopathy]. Rev Med Interne 1992;13(5):381-383.
  • 43929Hanisch, F. and Zierz, S. Only transient increase of serum CoQ subset 10 during long-term CoQ10 therapy in mitochondrial ophthalmoplegia. Eur.J Med.Res 11-12-2003;8(11):485-491.
  • 43932Rosenfeldt F., Hilton D., Pepe S., Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003;18:91-100.
  • 43933Shults, C. W., Flint, Beal M., Song, D., and Fontaine, D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp.Neurol. 2004;188(2):491-494.
  • 43934Aure, K., Benoist, J. F., Ogier, de Baulny, Romero, N. B., Rigal, O., and Lombes, A. Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology 8-24-2004;63(4):727-729.
  • 43935Damian, M. S., Ellenberg, D., Gildemeister, R., Lauermann, J., Simonis, G., Sauter, W., and Georgi, C. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. Circulation 11-9-2004;110(19):3011-3016.
  • 43936Silver, M. A., Langsjoen, P. H., Szabo, S., Patil, H., and Zelinger, A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 11-15-2004;94(10):1306-1310.
  • 43937Rosenfeldt, F., Marasco, S., Lyon, W., Wowk, M., Sheeran, F., Bailey, M., Esmore, D., Davis, B., Pick, A., Rabinov, M., Smith, J., Nagley, P., and Pepe, S. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac.Cardiovasc.Surg. 2005;129(1):25-32.
  • 43938van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev 2005;(1):CD003917.
  • 43940Reid, M. S., Casadonte, P., Baker, S., Sanfilipo, M., Braunstein, D., Hitzemann, R., Montgomery, A., Majewska, D., Robinson, J., and Rotrosen, J. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100 Suppl 1:43-57.
  • 43941Forgionne, G. A. Bovine cartilage, coenzyme Q10, and wheat grass therapy for primary peritoneal cancer. J Altern.Complement Med 2005;11(1):161-165.
  • 43942Hoenjet, K. M., Dagnelie, P. C., Delaere, K. P., Wijckmans, N. E., Zambon, J. V., and Oosterhof, G. O. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. Eur Urol 2005;47(4):433-439.
  • 43943Hart, P. E., Lodi, R., Rajagopalan, B., Bradley, J. L., Crilley, J. G., Turner, C., Blamire, A. M., Manners, D., Styles, P., Schapira, A. H., and Cooper, J. M. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch.Neurol. 2005;62(4):621-626.
  • 43944Bentler, S. E., Hartz, A. J., and Kuhn, E. M. Prospective observational study of treatments for unexplained chronic fatigue. J Clin Psychiatry 2005;66(5):625-632.
  • 43945Cicero, A. F., Derosa, G., Miconi, A., Laghi, L., Nascetti, S., and Gaddi, A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomed Pharmacother 2005;59(6):312-317.
  • 43946Feher, J., Kovacs, B., Kovacs, I., Schveoller, M., Papale, A., and Balacco, Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica 2005;219(3):154-166.
  • 43947Maeda, K., Tatsumi, M., Tahara, M., Murata, Y., Kawai, H., and Yasuda, H. [A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone]. Rinsho Shinkeigaku 2005;45(6):416-421.
  • 43949Witte, K. K., Nikitin, N. P., Parker, A. C., von Haehling, S., Volk, H. D., Anker, S. D., Clark, A. L., and Cleland, J. G. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005;26(21):2238-2244.
  • 43950Salviati, L., Sacconi, S., Murer, L., Zacchello, G., Franceschini, L., Laverda, A. M., Basso, G., Quinzii, C., Angelini, C., Hirano, M., Naini, A. B., Navas, P., DiMauro, S., and Montini, G. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 8-23-2005;65(4):606-608.
  • 43951Zaffanello, M. and Zamboni, G. Therapeutic approach in a case of Pearson’s syndrome. Minerva Pediatr 2005;57(3):143-146.
  • 43954Salles, J. E., Moises, V. A., Almeida, D. R., Chacra, A. R., and Moises, R. S. Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. Diabetes Res Clin Pract 2006;72(1):100-103.
  • 43955Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O’Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M. F., Traynor, B., Newhall, K., Donofrio, P., Caress, J., Ashburn, C., Freiberg, B., O’Neill, C., Paladenech, C., Walker, T., Pestronk, A., Abrams, B., Florence, J., Renna, R., Schierbecker, J., Malkus, B., and Cudkowicz, M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 12-13-2005;65(11):1834-1836.
  • 43956Mohr, D., Bowry, V. W., and Stocker, R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 6-26-1992;1126(3):247-254.
  • 43957Horvath, R., Schneiderat, P., Schoser, B. G., Gempel, K., Neuen-Jacob, E., Ploger, H., Muller-Hocker, J., Pongratz, D. E., Naini, A., DiMauro, S., and Lochmuller, H. Coenzyme Q10 deficiency and isolated myopathy. Neurology 1-24-2006;66(2):253-255.
  • 43958Chinnery, P., Majamaa, K., Turnbull, D., and Thorburn, D. Treatment for mitochondrial disorders. Cochrane Database Syst.Rev. 2006;(1):CD004426.
  • 43959Rusciani, L., Proietti, I., Rusciani, A., Paradisi, A., Sbordoni, G., Alfano, C., Panunzi, S., De Gaetano, A., and Lippa, S. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 2006;54(2):234-241.
  • 43960Tawankanjanachot, I., Channarong, N. S., and Phanthumchinda, K. Auditory symptoms: a critical clue for diagnosis of MELAS. J Med Assoc Thai. 2005;88(11):1715-1720.
  • 43961Levy, G., Kaufmann, P., Buchsbaum, R., Montes, J., Barsdorf, A., Arbing, R., Battista, V., Zhou, X., Mitsumoto, H., Levin, B., and Thompson, J. L. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 3-14-2006;66(5):660-663.
  • 43962Artuch, R., Brea-Calvo, G., Briones, P., Aracil, A., Galvan, M., Espinos, C., Corral, J., Volpini, V., Ribes, A., Andreu, A. L., Palau, F., Sanchez-Alcazar, J. A., Navas, P., and Pineda, M. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol.Sci 7-15-2006;246(1-2):153-158.
  • 43963Hirano, M., Quinzii, C. M., and DiMauro, S. Restoring balance to ataxia with coenzyme Q10 deficiency. J Neurol.Sci 7-15-2006;246(1-2):11-12.
  • 43965Belaia, O. L., Kalmykova, V. I., Ivanova, L. A., and Kochergina, L. G. [Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia]. Klin Med (Mosk) 2006;84(5):59-62.
  • 43966Islam, J., Uretsky, B. F., and Sierpina, V. S. Heart failure improvement with CoQ10, Hawthorn, and magnesium in a patient scheduled for cardiac resynchronization-defibrillator therapy: a case study. Explore.(NY) 2006;2(4):339-341.
  • 43967Belardinelli R, Muçaj A, Lacalaprice F, et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 2005;25:137-45.
  • 43968Singh, R. B., Niaz, M. A., Kumar, A., Sindberg, C. D., Moesgaard, S., and Littarru, G. P. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors 2005;25(1-4):219-224.
  • 43969Gvozdjakova, A., Kucharska, J., Bartkovjakova, M., Gazdikova, K., and Gazdik, F. E. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 2005;25(1-4):235-240.
  • 43970Kang, H. C., Kim, H. D., Lee, Y. M., and Han, S. H. Landau-Kleffner syndrome with mitochondrial respiratory chain-complex I deficiency. Pediatr.Neurol. 2006;35(2):158-161.
  • 43971BBelardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006;27:2675-81.
  • 43972Ramelli, G. P., Gallati, S., Weis, J., Krahenbuhl, S., and Burgunder, J. M. Point mutation tRNA(Ser(UCN)) in a child with hearing loss and myoclonus epilepsy. J Child Neurol. 2006;21(3):253-255.
  • 43973Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12:464-72.
  • 43974Donovan, L. E. and Severin, N. E. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J Clin Endocrinol.Metab 2006;91(12):4737-4742.
  • 43975Galili, N., Sechman, E. V., Cerny, J., Mehdi, M., Mumtaz, M., Westervelt, P., Maguire, J., and Raza, A. Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10. Leuk.Res 2007;31(1):19-26.
  • 43976Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., and Tarnopolsky, M. A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35(2):235-242.
  • 43977Letsas, K. P., Efremidis, M., Pappas, L. K., Gavrielatos, G., Sideris, A., and Charitos, C. Pathophysiology and management of syncope in Kearns-Sayre syndrome. Am Heart Hosp.J 2006;4(4):301-302.
  • 43978Nishino, M., Usami, M., Sugimura, S., and Yoshizaki, S. [Case of drug-induced pneumonitis associated with a dietary supplement containing CoQ10]. Nihon Kokyuki.Gakkai Zasshi 2006;44(10):766-770.
  • 43979Schulz, C., Obermuller-Jevic, U. C., Hasselwander, O., Bernhardt, J., and Biesalski, H. K. Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10). Int J Food Sci Nutr 2006;57(7-8):546-555.
  • 43980Lopez, L. C., Schuelke, M., Quinzii, C. M., Kanki, T., Rodenburg, R. J., Naini, A., DiMauro, S., and Hirano, M. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum.Genet. 2006;79(6):1125-1129.
  • 43981Khan, M., Gross, J., Haupt, H., Jainz, A., Niklowitz, P., Scherer, H., Schmidt, F. P., Klapp, B. F., Reisshauer, A., and Mazurek, B. A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium. Otolaryngol.Head Neck Surg 2007;136(1):72-77.
  • 43982Rosenfeldt, F. L., Haas, S. J., Krum, H., Hadj, A., Ng, K., Leong, J. Y., and Watts, G. F. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum.Hypertens. 2007;21(4):297-306.
  • 43983Folkers, K., Langsjoen, P., and Langsjoen, P. H. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys.Res Commun. 1-15-1992;182(1):247-253.
  • 43985Geng, A., Li, B., and Guo, Y. Effects of dietary L-carnitine and coenzyme Q10 at different supplemental ages on growth performance and some immune response in ascites-susceptible broilers. Arch.Anim Nutr. 2007;61(1):50-60.
  • 43986Keith, M., Mazer, C. D., Mikhail, P., Jeejeebhoy, F., Briet, F., and Errett, L. Coenzyme Q10 in patients undergoing CABG: Effect of statins and nutritional supplementation. Nutr Metab Cardiovasc.Dis. 2008;18(2):105-111.
  • 43987Niklowitz, P., Sonnenschein, A., Janetzky, B., Andler, W., and Menke, T. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage. Int J Biol Sci 2007;3(4):257-262.
  • 43988Rusciani, L., Proietti, I., Paradisi, A., Rusciani, A., Guerriero, G., Mammone, A., De Gaetano, A., and Lippa, S. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up. Melanoma Res 2007;17(3):177-183.
  • 43989Storch, A. [Coenzyme Q10 in Parkinson’s disease. Symptomatic or neuroprotective effects?]. Nervenarzt 2007;78(12):1378-1382.
  • 43990Papas, K. A., Sontag, M. K., Pardee, C., Sokol, R. J., Sagel, S. D., Accurso, F. J., and Wagener, J. S. A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. J Cyst.Fibros. 2008;7(1):60-67.
  • 43991Tiano, L., Belardinelli, R., Carnevali, P., Principi, F., Seddaiu, G., and Littarru, G. P. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur.Heart J 2007;28(18):2249-2255.
  • 43992Yuvaraj, S., Premkumar, V. G., Vijayasarathy, K., Gangadaran, S. G., and Sachdanandam, P. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin. Cancer Chemother.Pharmacol 2008;61(6):933-941.
  • 43993Tsujita, Y., Kunitomo, T., Fujii, M., Furukawa, S., Otsuki, H., Fujino, K., Hamamoto, T., Tabata, T., Matsumura, K., Sasaki, T., Saotome, T., Kawai, H., Matsumoto, T., Maeda, K., Horie, M., and Eguchi, Y. A surviving case of mitochondrial cardiomyopathy diagnosed from the symptoms of multiple organ dysfunction syndrome. Int J Cardiol. 8-1-2008;128(1):e43-e45.
  • 43994Satta, A., Grandi, M., Landoni, C. V., Migliori, G. B., Spanevello, A., Vocaturo, G., and Neri, M. Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases. Clin Ther. 1991;13(6):754-757.
  • 43996Murata, T., Ohtsuka, C., and Terayama, Y. Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol.Sci 4-15-2008;267(1-2):66-69.
  • 43997Myers, L., Farmer, J. M., Wilson, R. B., Friedman, L., Tsou, A., Perlman, S. L., Subramony, S. H., Gomez, C. M., Ashizawa, T., Wilmot, G. R., Mathews, K. D., Balcer, L. J., and Lynch, D. R. Antioxidant use in Friedreich ataxia. J Neurol.Sci 4-15-2008;267(1-2):174-176.
  • 44000Mizushina, Y., Takeuchi, T., Takakusagi, Y., Yonezawa, Y., Mizuno, T., Yanagi, K., Imamoto, N., Sugawara, F., Sakaguchi, K., Yoshida, H., and Fujita, M. Coenzyme Q10 as a potent compound that inhibits Cdt1-geminin interaction. Biochim.Biophys.Acta 2008;1780(2):203-213.
  • 44002Yang, X., Yang, Y., Li, G., Wang, J., and Yang, E. S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol.Neurosci. 2008;34(2):165-171.
  • 44003Pineda, M., Arpa, J., Montero, R., Aracil, A., Dominguez, F., Galvan, M., Mas, A., Martorell, L., Sierra, C., Brandi, N., Garcia-Arumi, E., Rissech, M., Velasco, D., Costa, J. A., and Artuch, R. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr.Neurol. 2008;12(6):470-475.
  • 44004Senes, M., Erbay, A. R., Yilmaz, F. M., Topkaya, B. C., Zengi, O., Dogan, M., and Yucel, D. Coenzyme Q10 and high-sensitivity C-reactive protein in ischemic and idiopathic dilated cardiomyopathy. Clin Chem.Lab Med 2008;46(3):382-386.
  • 44005Eiholzer, U., Meinhardt, U., Rousson, V., Petrovic, N., Schlumpf, M., and l’Allemand, D. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet.A 4-1-2008;146(7):873-880.
  • 44006Mizuno, K., Tanaka, M., Nozaki, S., Mizuma, H., Ataka, S., Tahara, T., Sugino, T., Shirai, T., Kajimoto, Y., Kuratsune, H., Kajimoto, O., and Watanabe, Y. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition 2008;24(4):293-299.
  • 44007Kon, M., Tanabe, K., Akimoto, T., Kimura, F., Tanimura, Y., Shimizu, K., Okamoto, T., and Kono, I. Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10. Br J Nutr 2008;100(4):903-909.
  • 44009Murata, T., Ohtsuka, C., and Terayama, Y. Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis. Free Radic.Res 2008;42(3):221-225.
  • 44012LeWitt, P. A. and Taylor, D. C. Protection against Parkinson’s disease progression: clinical experience. Neurotherapeutics. 2008;5(2):210-225.
  • 44013Balercia, G., Buldreghini, E., Vignini, A., Tiano, L., Paggi, F., Amoroso, S., Ricciardo-Lamonica, G., Boscaro, M., Lenzi, A., and Littarru, G. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil.Steril. 2009;91(5):1785-1792.
  • 44015Premkumar, V. G., Yuvaraj, S., Sathish, S., Shanthi, P., and Sachdanandam, P. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul.Pharmacol. 2008;48(4-6):191-201.
  • 44016van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev. 2008;(2):CD003917.
  • 44017Santa-Mara, I., Santpere, G., MacDonald, M. J., Gomez de, Barreda E., Hernandez, F., Moreno, F. J., Ferrer, I., and Avila, J. Coenzyme q induces tau aggregation, tau filaments, and Hirano bodies. J Neuropathol.Exp.Neurol. 2008;67(5):428-434.
  • 44018Braun, B., Clarkson, P. M., Freedson, P. S., and Kohl, R. L. Effects of coenzyme Q10 supplementation on exercise performance, VO2max, and lipid peroxidation in trained cyclists. Int J Sport Nutr. 1991;1(4):353-365.
  • 44019Voronkova, K. V. and Meleshkov, M. N. [Noben (idebenone) in the treatment of dementia and memory impairment without dementia]. Zh.Nevrol.Psikhiatr.Im S.S.Korsakova 2008;108(4):27-32.
  • 44020Stamelou, M., Reuss, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K. M., Krisp, A., Menke, T., Schade-Brittinger, C., Oertel, W. H., and Hoglinger, G. U. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 5-15-2008;23(7):942-949.
  • 44021Pepe, S., Leong, J. Y., Van der Merwe, J., Marasco, S. F., Hadj, A., Lymbury, R., Perkins, A., and Rosenfeldt, F. L. Targeting oxidative stress in surgery: effects of ageing and therapy. Exp.Gerontol. 2008;43(7):653-657.
  • 44023Chew, G. T., Watts, G. F., Davis, T. M., Stuckey, B. G., Beilin, L. J., Thompson, P. L., Burke, V., and Currie, P. J. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008;31(8):1502-1509.
  • 44024Harinstein, M. E., Berliner, J. I., Shah, S. J., Taegtmeyer, H., and Gheorghiade, M. Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observations in 11 patients. Am J Ther 2008;15(3):206-213.
  • 44026Gruber, J., Schaffer, S., and Halliwell, B. The mitochondrial free radical theory of ageing–where do we stand? Front Biosci 2008;13:6554-6579.
  • 44027Sakata, T., Furuya, R., Shimazu, T., Odamaki, M., Ohkawa, S., and Kumagai, H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008;26(4):371-378.
  • 44028Ravina, B., Romer, M., Constantinescu, R., Biglan, K., Brocht, A., Kieburtz, K., Shoulson, I., and McDermott, M. P. The relationship between CAG repeat length and clinical progression in Huntington’s disease. Mov Disord. 7-15-2008;23(9):1223-1227.
  • 44029Laguna, T. A., Sontag, M. K., Osberg, I., Wagener, J. S., Accurso, F. J., and Sokol, R. J. Decreased total serum coenzyme-Q10 concentrations: a longitudinal study in children with cystic fibrosis. J Pediatr 2008;153(3):402-407.
  • 44031Sunamori, M., Tanaka, H., Maruyama, T., Sultan, I., Sakamoto, T., and Suzuki, A. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization. Cardiovasc.Drugs Ther 1991;5 Suppl 2:297-300.
  • 44034Montini, G., Malaventura, C., and Salviati, L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N.Engl.J Med 6-26-2008;358(26):2849-2850.
  • 44035Schmitz-Hubsch, T. and Klockgether, T. An update on inherited ataxias. Curr Neurol.Neurosci.Rep. 2008;8(4):310-319.
  • 44036Jimenez-Caballero, P. E., Mollejo-Villanueva, M., and Alvarez-Tejerina, A. [Mitochondrial encephalopathy due to complex I deficiency. Brain tissue biopsy findings and clinical course following pharmacological]. Rev.Neurol. 7-1-2008;47(1):27-30.
  • 44039Miles, M. V., Tang, P. H., Miles, L., Steele, P. E., Moye, M. J., and Horn, P. S. Validation and application of an HPLC-EC method for analysis of coenzyme Q10 in blood platelets. Biomed.Chromatogr. 2008;22(12):1403-1408.
  • 44040Tauler, P., Ferrer, M. D., Sureda, A., Pujol, P., Drobnic, F., Tur, J. A., and Pons, A. Supplementation with an antioxidant cocktail containing coenzyme Q prevents plasma oxidative damage induced by soccer. Eur J Appl.Physiol 2008;104(5):777-785.
  • 44041Menke, T., Niklowitz, P., Wiesel, T., and Andler, W. Antioxidant level and redox status of coenzyme Q10 in the plasma and blood cells of children with diabetes mellitus type 1. Pediatr Diabetes 2008;9(6):540-545.
  • 44042Keogh A, Fenton S, Leslie C, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ. 2003;12:135-41.
  • 44045Tonon, C. and Lodi, R. Idebenone in Friedreich’s ataxia. Expert.Opin.Pharmacother. 2008;9(13):2327-2337.
  • 44046Esteves, A. R., Arduino, D. M., Swerdlow, R. H., Oliveira, C. R., and Cardoso, S. M. Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson’s disease cybrids. Antioxid.Redox.Signal. 2009;11(3):439-448.
  • 44049Zheng, A. and Moritani, T. Influence of CoQ10 on autonomic nervous activity and energy metabolism during exercise in healthy subjects. J Nutr Sci Vitaminol.(Tokyo) 2008;54(4):286-290.
  • 44050Makhija, N., Sendasgupta, C., Kiran, U., Lakshmy, R., Hote, M. P., Choudhary, S. K., Airan, B., and Abraham, R. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. J Cardiothorac.Vasc.Anesth. 2008;22(6):832-839.
  • 44051Gregersen, N., Andresen, B. S., Pedersen, C. B., Olsen, R. K., Corydon, T. J., and Bross, P. Mitochondrial fatty acid oxidation defects–remaining challenges. J Inherit.Metab Dis 2008;31(5):643-657.
  • 44054Skough, K., Krossen, C., Heiwe, S., Theorell, H., and Borg, K. Effects of resistance training in combination with coenzyme Q10 supplementation in patients with post-polio: a pilot study. J Rehabil.Med 2008;40(9):773-775.
  • 44058Henchcliffe, C. and Beal, M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat.Clin Pract Neurol. 2008;4(11):600-609.
  • 44059Molyneux, S. L., Florkowski, C. M., George, P. M., Pilbrow, A. P., Frampton, C. M., Lever, M., and Richards, A. M. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll.Cardiol. 10-28-2008;52(18):1435-1441.
  • 44060Horvath, R., Gorman, G., and Chinnery, P. F. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics. 2008;5(4):558-568.
  • 44061Caramia, G., Cocchi, M., Tonello, L., and Visci, G. [Childhood obesity: recent advances and an experimental contribution]. Pediatr Med Chir 2008;30(3):121-140.
  • 44063Kharaeva, Z., Gostova, E., de, Luca C., Raskovic, D., and Korkina, L. Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. Nutrition 2009;25(3):295-302.
  • 44064Cooper, J. M., Korlipara, L. V., Hart, P. E., Bradley, J. L., and Schapira, A. H. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur.J Neurol. 2008;15(12):1371-1379.
  • 44065Wang, S. B., Weng, W. C., Lee, N. C., Hwu, W. L., Fan, P. C., and Lee, W. T. Mutation of mitochondrial DNA G13513A presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr.Neonatol. 2008;49(4):145-149.
  • 44067Lee, T. I., Kao, Y. H., Chen, Y. C., and Chen, Y. J. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Eur.J Clin Invest 2009;39(1):23-30.
  • 44072Montero, R., Sanchez-Alcazar, J. A., Briones, P., Navarro-Sastre, A., Gallardo, E., Bornstein, B., Herrero-Martin, D., Rivera, H., Martin, M. A., Marti, R., Garcia-Cazorla, A., Montoya, J., Navas, P., and Artuch, R. Coenzyme Q10 deficiency associated with a mitochondrial DNA depletion syndrome: a case report. Clin Biochem. 2009;42(7-8):742-745.
  • 44075Langsjoen, P. H. and Langsjoen, A. M. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128.
  • 44076Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors 2008;32:145-9.
  • 44077Teran, E., Chedraui, P., Racines-Orbe, M., Vivero, S., Villena, F., Duchicela, F., Nacevilla, L., Schwager, G., and Calle, A. Coenzyme Q10 levels in women with preeclampsia living at different altitudes. Biofactors 2008;32(1-4):185-190.
  • 44078Hidaka, T., Fujii, K., Funahashi, I., Fukutomi, N., and Hosoe, K. Safety assessment of coenzyme Q10 (CoQ10). Biofactors 2008;32(1-4):199-208.
  • 44080Morre, D. M., Morre, D. J., Rehmus, W., and Kern, D. Supplementation with CoQ10 lowers age-related (ar) NOX levels in healthy subjects. Biofactors 2008;32(1-4):221-230.
  • 44081Morre, D. J. and Morre, D. M. arNOX activity of saliva as a non-invasive measure of coenzyme Q10 response in human trials. Biofactors 2008;32(1-4):231-235.
  • 44082Inui, M., Ooe, M., Fujii, K., Matsunaka, H., Yoshida, M., and Ichihashi, M. Mechanisms of inhibitory effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. Biofactors 2008;32(1-4):237-243.
  • 44084Haginoya, K., Miyabayashi, S., Kikuchi, M., Kojima, A., Yamamoto, K., Omura, K., Uematsu, M., Hino-Fukuyo, N., Tanaka, S., and Tsuchiya, S. Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study. J Neurol.Sci 3-15-2009;278(1-2):112-114.
  • 44085Rodriguez-Hernandez, A., Cordero, M. D., Salviati, L., Artuch, R., Pineda, M., Briones, P., Gomez, Izquierdo L., Cotan, D., Navas, P., and Sanchez-Alcazar, J. A. Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. Autophagy. 1-1-2009;5(1):19-32.
  • 44087Bergamin, C. S., Rolim, L. C., Dib, S. A., and Moises, R. S. Unusual occurrence of intestinal pseudo obstruction in a patient with maternally inherited diabetes and deafness (MIDD) and favorable outcome with coenzyme Q10. Arq Bras.Endocrinol Metabol. 2008;52(8):1345-1349.
  • 44088Hamilton, S. J., Chew, G. T., and Watts, G. F. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 2009;32(5):810-812.
  • 44090Dunn, S. P., Bleske, B., Dorsch, M., Macaulay, T., Van, Tassell B., and Vardeny, O. Nutrition and heart failure: impact of drug therapies and management strategies. Nutr Clin Pract 2009;24(1):60-75.
  • 44091Rakoczi, K., Klivenyi, P., and Vecsei, L. [Neuroprotection in Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical findings]. Ideggyogy.Sz 1-30-2009;62(1-2):25-34.
  • 44092Celik, T. and Iyisoy, A. Coenzyme Q10 and coronary artery bypass surgery: what we have learned from clinical trials. J Cardiothorac.Vasc.Anesth. 2009;23(6):935-936.
  • 44094Pandolfo, M. Introduction. Idebenone in the treatment of Friedreich ataxia. J Neurol. 2009;256 Suppl 1:1-2.
  • 44095Meier, T. and Buyse, G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol. 2009;256 Suppl 1:25-30.
  • 44097Schulz, J. B., Di Prospero, N. A., and Fischbeck, K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol. 2009;256 Suppl 1:42-45.
  • 44098Liu, Z. X. and Artmann, C. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Altern.Ther Health Med 2009;15(2):42-46.
  • 44099Tsou, A. Y., Friedman, L. S., Wilson, R. B., and Lynch, D. R. Pharmacotherapy for Friedreich ataxia. CNS.Drugs 2009;23(3):213-223.
  • 44101Rinaldi, C., Tucci, T., Maione, S., Giunta, A., De, Michele G., and Filla, A. Low-dose idebenone treatment in Friedreich’s ataxia with and without cardiac hypertrophy. J Neurol. 2009;256(9):1434-1437.
  • 44102Duncan, A. J., Bitner-Glindzicz, M., Meunier, B., Costello, H., Hargreaves, I. P., Lopez, L. C., Hirano, M., Quinzii, C. M., Sadowski, M. I., Hardy, J., Singleton, A., Clayton, P. T., and Rahman, S. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet. 2009;84(5):558-566.
  • 44103D’Andrea, G., Bussone, G., Allais, G., Aguggia, M., D’Onofrio, F., Maggio, M., Moschiano, F., Saracco, M. G., Terzi, M. G., Petretta, V., and Benedetto, C. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol.Sci 2009;30 Suppl 1:S121-S124.
  • 44104Voronkova, K. V. and Meleshkov, M. N. Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia. Neurosci.Behav.Physiol 2009;39(5):501-506.
  • 44107Bolognesi, M. L., Matera, R., Minarini, A., Rosini, M., and Melchiorre, C. Alzheimer’s disease: new approaches to drug discovery. Curr Opin.Chem Biol. 2009;13(3):303-308.
  • 44108Sinatra, S. T. Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern.Ther Health Med. 2009;15(3):44-52.
  • 44109Ramirez-Tortosa, M. C., Quiles, J. L., Battino, M., Granados, S., Morillo, J. M., Bompadre, S., Newman, H. N., and Bullon, P. Periodontitis is associated with altered plasma fatty acids and cardiovascular risk markers. Nutr Metab Cardiovasc.Dis 2010;20(2):133-139.
  • 44110Balercia, G., Mancini, A., Paggi, F., Tiano, L., Pontecorvi, A., Boscaro, M., Lenzi, A., and Littarru, G. P. Coenzyme Q10 and male infertility. J Endocrinol Invest 2009;32(7):626-632.
  • 44112Kaji, S., Murayama, K., Nagata, I., Nagasaka, H., Takayanagi, M., Ohtake, A., Iwasa, H., Nishiyama, M., Okazaki, Y., Harashima, H., Eitoku, T., Yamamoto, M., Matsushita, H., Kitamoto, K., Sakata, S., Katayama, T., Sugimoto, S., Fujimoto, Y., Murakami, J., Kanzaki, S., and Shiraki, K. Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II. Mol.Genet.Metab 2009;97(4):292-296.
  • 44114El-ghoroury, E. A., Raslan, H. M., Badawy, E. A., El-Saaid, G. S., Agybi, M. H., Siam, I., and Salem, S. I. Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic control. Blood Coagul.Fibrinolysis 2009;20(4):248-251.
  • 44115Udompataikul, M., Sripiroj, P., and Palungwachira, P. An oral nutraceutical containing antioxidants, minerals and glycosaminoglycans improves skin roughness and fine wrinkles. Int.J Cosmet.Sci 2009;31(6):427-435.
  • 44116Ferrer, M. D., Tauler, P., Sureda, A., Pujol, P., Drobnic, F., Tur, J. A., and Pons, A. A soccer match’s ability to enhance lymphocyte capability to produce ROS and induce oxidative damage. Int.J Sport Nutr Exerc.Metab 2009;19(3):243-258.
  • 44117Mestre, T., Ferreira, J., Coelho, M. M., Rosa, M., and Sampaio, C. Therapeutic interventions for disease progression in Huntington’s disease. Cochrane.Database.Syst.Rev. 2009;(3):CD006455.
  • 44118Golomb, B. A., Kwon, E. K., Koperski, S., and Evans, M. A. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf 2009;32(8):649-661.
  • 44119Parashos, S. A., Swearingen, C. J., Biglan, K. M., Bodis-Wollner, I., Liang, G. S., Ross, G. W., Tilley, B. C., and Shulman, L. M. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009;66(9):1099-1104.
  • 44120Scarlato, G., Bresolin, N., Moroni, I., Doriguzzi, C., Castelli, E., Comi, G., Angelini, C., and Carenzi, A. Multicenter trial with ubidecarenone: treatment of 44 patients with mitochondrial myopathies. Rev Neurol.(Paris) 1991;147(6-7):542-548.
  • 44122Gokbel, H., Gul, I., Belviranl, M., and Okudan, N. The effects of coenzyme Q10 supplementation on performance during repeated bouts of supramaximal exercise in sedentary men. J Strength Cond.Res 2010;24(1):97-102.
  • 44124Sivitz, W. I. and Yorek, M. A. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid.Redox.Signal. 2010;12(4):537-577.
  • 44126Orsucci, D., Filosto, M., Siciliano, G., and Mancuso, M. Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev. 2009;67(8):427-438.
  • 44127Kocharian, A., Shabanian, R., Rafiei-Khorgami, M., Kiani, A., and Heidari-Bateni, G. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiol.Young. 2009;19(5):501-506.
  • 44128Journal of Basic and Clinical Physiology and Pharmacology, Volume 28, Issue 4, Pages 327–336, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855
  • 44130Bentov, Y., Esfandiari, N., Burstein, E., and Casper, R. F. The use of mitochondrial nutrients to improve the outcome of infertility treatment in older patients. Fertil.Steril. 2010;93(1):272-275.
  • 44131Kaufmann, P., Thompson, J. L., Levy, G., Buchsbaum, R., Shefner, J., Krivickas, L. S., Katz, J., Rollins, Y., Barohn, R. J., Jackson, C. E., Tiryaki, E., Lomen-Hoerth, C., Armon, C., Tandan, R., Rudnicki, S. A., Rezania, K., Sufit, R., Pestronk, A., Novella, S. P., Heiman-Patterson, T., Kasarskis, E. J., Pioro, E. P., Montes, J., Arbing, R., Vecchio, D., Barsdorf, A., Mitsumoto, H., and Levin, B. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235-244.
  • 44133Muta-Takada, K., Terada, T., Yamanishi, H., Ashida, Y., Inomata, S., Nishiyama, T., and Amano, S. Coenzyme Q10 protects against oxidative stress-induced cell death and enhances the synthesis of basement membrane components in dermal and epidermal cells. Biofactors 2009;35(5):435-441.
  • 44134Sival, D. A., du Marchie Sarvaas, G. J., Brouwer, O. F., Uges, D. R., Verschuuren-Bemelmans, C. C., Maurits, N. M., Brunt, E. R., and van der Hoeven, J. H. Neurophysiological evaluation in children with Friedreich’s ataxia. Early Hum.Dev. 2009;85(10):647-651.
  • 44135Patel, B. P. and Hamadeh, M. J. Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clin Nutr. 2009;28(6):604-617.
  • 44136Isobe, C., Abe, T., and Terayama, Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the CSF of patients with Alzheimer’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J Neurol. 2010;257(3):399-404.
  • 44137Lee, D. S., Badr, M. S., and Mateika, J. H. Progressive augmentation and ventilatory long-term facilitation are enhanced in sleep apnoea patients and are mitigated by antioxidant administration. J Physiol 11-15-2009;587(Pt 22):5451-5467.
  • 44138Kearney, M., Orrell, R. W., Fahey, M., and Pandolfo, M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst.Rev. 2009;(4):CD007791.
  • 44139Jacobson, B. H., Smith, D. B., Warren, A. J., Glass, R. G., Kline, C., Fedick, J. L., and Stemm, J. Assessment of the effectiveness of a sublingual, ergogenic spray on muscle strength and power. J Strength Cond.Res 2009;23(8):2326-2330.
  • 44140Yang, X., Dai, G., Li, G., and Yang, E. S. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer’s disease. J Mol.Neurosci. 2010;41(1):110-113.
  • 44141Soukoulis, V., Dihu, J. B., Sole, M., Anker, S. D., Cleland, J., Fonarow, G. C., Metra, M., Pasini, E., Strzelczyk, T., Taegtmeyer, H., and Gheorghiade, M. Micronutrient deficiencies an unmet need in heart failure. J Am Coll.Cardiol. 10-27-2009;54(18):1660-1673.
  • 44142Azevedo, O., Vilarinho, L., Almeida, F., Ferreira, F., Guardado, J., Ferreira, M., Lourenco, A., Medeiros, R., and Almeida, J. Cardiomyopathy and kidney disease in a patient with maternally inherited diabetes and deafness caused by the 3243A>G mutation of mitochondrial DNA. Cardiology 2010;115(1):71-74.
  • 44143Fetoni, A. R., Garzaro, M., Ralli, M., Landolfo, V., Sensini, M., Pecorari, G., Mordente, A., Paludetti, G., and Giordano, C. The monitoring role of otoacoustic emissions and oxidative stress markers in the protective effects of antioxidant administration in noise-exposed subjects: a pilot study. Med Sci Monit. 2009;15(11):R1-R8.
  • 44145Someya, S., Xu, J., Kondo, K., Ding, D., Salvi, R. J., Yamasoba, T., Rabinovitch, P. S., Weindruch, R., Leeuwenburgh, C., Tanokura, M., and Prolla, T. A. Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc.Natl.Acad.Sci U.S.A 11-17-2009;106(46):19432-19437.
  • 44146Isobe, C., Abe, T., and Terayama, Y. Increase in the oxidized/total coenzyme Q-10 ratio in the cerebrospinal fluid of Alzheimer’s disease patients. Dement.Geriatr.Cogn Disord. 2009;28(5):449-454.
  • 44148Isobe, C., Abe, T., and Terayama, Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci.Lett. 1-18-2010;469(1):159-163.
  • 44149Sacconi, S., Trevisson, E., Salviati, L., Ayme, S., Rigal, O., Redondo, A. G., Mancuso, M., Siciliano, G., Tonin, P., Angelini, C., Aure, K., Lombes, A., and Desnuelle, C. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul.Disord. 2010;20(1):44-48.
  • 44150Molyneux, S. L., Florkowski, C. M., Richards, A. M., Lever, M., Young, J. M., and George, P. M. Coenzyme Q10; an adjunctive therapy for congestive heart failure? N.Z.Med J 10-30-2009;122(1305):74-79.
  • 44151Stocker, R., Bowry, V. W., and Frei, B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl.Acad Sci U.S.A 3-1-1991;88(5):1646-1650.
  • 44153Kerr, D. S. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol.Genet.Metab 2010;99(3):246-255.
  • 44154Beal, M. F. Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism.Relat Disord. 2009;15 Suppl 3:S189-S194.
  • 44155Sun, H. Y. [Clinical study of Wenxikeli treatment of viral myocarditis]. Zhonghua Shi Yan.He.Lin.Chuang.Bing.Du Xue.Za Zhi. 2009;23(2):144-145.
  • 44156Cordero, M. D., de, Miguel M., Moreno Fernandez, A. M., Carmona Lopez, I. M., Garrido, Maraver J., Cotan, D., Gomez, Izquierdo L., Bonal, P., Campa, F., Bullon, P., Navas, P., and Sanchez Alcazar, J. A. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 2010;12(1):R17.
  • 44158Roland, L., Gagne, A., Belanger, M. C., Boutet, M., Berthiaume, L., Fraser, W. D., Julien, P., and Bilodeau, J. F. Existence of compensatory defense mechanisms against oxidative stress and hypertension in preeclampsia. Hypertens.Pregnancy. 2010;29(1):21-37.
  • 44159Hertz, N. and Lister, R. E. Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study. J Int.Med Res 2009;37(6):1961-1971.
  • 44160Brookman, R. H. and St Cyr, J. A. Metabolic supplementation with enhanced external counterpulsation improves myocardial function in acquired cardiomyopathy: a case report. J Altern.Complement Med 2010;16(3):323-325.
  • 44161Thomas, B. and Beal, M. F. Mitochondrial therapies for Parkinson’s disease. Mov Disord. 2010;25 Suppl 1:S155-S160.
  • 44162Cornelli, U. Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener.Dis 2010;7(1-3):193-202.
  • 44165Hauser, R. A. Early pharmacologic treatment in Parkinson’s disease. Am J Manag.Care 2010;16 Suppl Implications:S100-S107.
  • 44166Chen, J. J. Parkinson’s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag.Care 2010;16 Suppl Implications:S87-S93.
  • 44167Cadoni, G., Scorpecci, A., Cianfrone, F., Giannantonio, S., Paludetti, G., and Lippa, S. Serum fatty acids and cardiovascular risk factors in sudden sensorineural hearing loss: a case-control study. Ann Otol.Rhinol.Laryngol. 2010;119(2):82-88.
  • 44168Ozaki, A., Muromachi, A., Sumi, M., Sakai, Y., Morishita, K., and Okamoto, T. Emulsification of coenzyme Q10 using gum arabic increases bioavailability in rats and human and improves food-processing suitability. J Nutr Sci Vitaminol.(Tokyo) 2010;56(1):41-47.
  • 44169Bessler, H., Bergman, M., Blumberger, N., Djaldetti, M., and Salman, H. Coenzyme Q10 decreases TNF-alpha and IL-2 secretion by human peripheral blood mononuclear cells. J Nutr Sci Vitaminol.(Tokyo) 2010;56(1):77-81.
  • 44170Kernt, M., Hirneiss, C., Neubauer, A. S., Ulbig, M. W., and Kampik, A. Coenzyme Q10 prevents human lens epithelial cells from light-induced apoptotic cell death by reducing oxidative stress and stabilizing BAX / Bcl-2 ratio. Acta Ophthalmol. 2010;88(3):e78-e86.
  • 44171Salami, A., Mora, R., Dellepiane, M., Manini, G., Santomauro, V., Barettini, L., and Guastini, L. Water-soluble coenzyme Q10 formulation (Q-TER((R))) in the treatment of presbycusis. Acta Otolaryngol. 2010;130(10):1154-1162.
  • 44172Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A., and Murphy, M. P. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019-1026.
  • 44174Gerards, M., van den Bosch, B., Calis, C., Schoonderwoerd, K., van, Engelen K., Tijssen, M., de, Coo R., van der Kooi, A., and Smeets, H. Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and atrophy. Mitochondrion. 2010;10(5):510-515.
  • 44175Drinkard, B. E., Keyser, R. E., Paul, S. M., Arena, R., Plehn, J. F., Yanovski, J. A., and Di Prospero, N. A. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch Phys.Med Rehabil. 2010;91(7):1044-1050.
  • 44176Cordero, M. D., Moreno-Fernandez, A. M., Carmona-Lopez, M. I., Sanchez-Alcazar, J. A., Rodriguez, A. F., Navas, P., and de, Miguel M. Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. Clin Biochem 2010;43(13-14):1174-1176.
  • 44177Pineda, M., Montero, R., Aracil, A., O’Callaghan, M. M., Mas, A., Espinos, C., Martinez-Rubio, D., Palau, F., Navas, P., Briones, P., and Artuch, R. Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up. Mov Disord. 7-15-2010;25(9):1262-1268.
  • 44178Belcaro, G., Cesarone, M. R., Dugall, M., Hosoi, M., Ippolito, E., Bavera, P., and Grossi, M. G. Investigation of Pycnogenol(R) in combination with coenzymeQ10 in heart failure patients (NYHA II/III). Panminerva Med 2010;52(2 Suppl 1):21-25.
  • 44179Lynch, D. R., Perlman, S. L., and Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67(8):941-947.
  • 44180Safarinejad, M. R. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot.Res 2010;22(5):298-309.
  • 44181Esposito, M. and Carotenuto, M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol.Sci 9-25-2010;
  • 44182Glover, E. I., Martin, J., Maher, A., Thornhill, R. E., Moran, G. R., and Tarnopolsky, M. A. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010;42(5):739-748.
  • 44183Sagel, S. D., Sontag, M. K., Anthony, M. M., Emmett, P., and Papas, K. A. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J Cyst.Fibros. 10-18-2010;
  • 44184Guastini, L., Mora, R., Dellepiane, M., Santomauro, V., Giorgio, M., and Salami, A. Water-soluble coenzyme Q10 formulation in presbycusis: long-term effects. Acta Otolaryngol. 2011;131(5):512-517.
  • 44185Ahn, J. H., Yoo, M. H., Lee, H. J., Chung, J. W., and Yoon, T. H. Coenzyme Q10 in combination with steroid therapy for treatment of sudden sensorineural hearing loss: a controlled prospective study. Clin Otolaryngol. 2010;35(6):486-489.
  • 44186Barker, P. D. Reduced G tolerance associated with supplement use. Aviat.Space Environ.Med 2011;82(2):140-143.
  • 44187Shojaei, M., Djalali, M., Khatami, M., Siassi, F., and Eshraghian, M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis 2011;5(2):114-118.
  • 44188Dai, Y. L., Luk, T. H., Yiu, K. H., Wang, M., Yip, P. M., Lee, S. W., Li, S. W., Tam, S., Fong, B., Lau, C. P., Siu, C. W., and Tse, H. F. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis 2011;216(2):395-401.
  • 44189Lagedrost, S. J., Sutton, M. S., Cohen, M. S., Satou, G. M., Kaufman, B. D., Perlman, S. L., Rummey, C., Meier, T., and Lynch, D. R. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 2011;161(3):639-645.
  • 44190Nadjarzadeh, A., Sadeghi, M. R., Amirjannati, N., Vafa, M. R., Motevalian, S. A., Gohari, M. R., Akhondi, M. A., Yavari, P., and Shidfar, F. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. J Endocrinol.Invest 2011;34(8):e224-e228.
  • 44191Ryo, K., Ito, A., Takatori, R., Tai, Y., Arikawa, K., Seido, T., Yamada, T., Shinpo, K., Tamaki, Y., Fujii, K., Yamamoto, Y., and Saito, I. Effects of coenzyme Q10 on salivary secretion. Clin Biochem 2011;44(8-9):669-674.
  • 44192Buyse, G. M., Goemans, N., van den Hauwe, M., Thijs, D., de Groot, I. J., Schara, U., Ceulemans, B., Meier, T., and Mertens, L. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul.Disord. 2011;21(6):396-405.
  • 44193Fumagalli, S., Fattirolli, F., Guarducci, L., Cellai, T., Baldasseroni, S., Tarantini, F., Di, Bari M., Masotti, G., and Marchionni, N. Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol. 2011;34(4):211-217.
  • 44194Cooney, R. V., Dai, Q., Gao, Y. T., Chow, W. H., Franke, A. A., Shu, X. O., Li, H., Ji, B., Cai, Q., Chai, W., and Zheng, W. Low plasma coenzyme Q(10) levels and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1124-1130.
  • 44195Cordero, M. D., Alcocer-Gomez, E., de, Miguel M., Cano-Garcia, F. J., Luque, C. M., Fernandez-Riejo, P., Fernandez, A. M., and Sanchez-Alcazar, J. A. Coenzyme Q(10): a novel therapeutic approach for Fibromyalgia? case series with 5 patients. Mitochondrion. 2011;11(4):623-625.
  • 44196Lekoubou, A., Kouame-Assouan, A. E., Cho, T. H., Luaute, J., Nighoghossian, N., and Derex, L. Effect of long-term oral treatment with L-arginine and idebenone on the prevention of stroke-like episodes in an adult MELAS patient. Rev.Neurol.(Paris) 2011;167(11):852-855.
  • 44197Slater, S. K., Nelson, T. D., Kabbouche, M. A., Lecates, S. L., Horn, P., Segers, A., Manning, P., Powers, S. W., and Hershey, A. D. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011;31(8):897-905.
  • 44198van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev. 2011;(6):CD003917.
  • 44199Gul, I., Gokbel, H., Belviranli, M., Okudan, N., Buyukbas, S., and Basarali, K. Oxidative stress and antioxidant defense in plasma after repeated bouts of supramaximal exercise: the effect of coenzyme Q10. J Sports Med Phys.Fitness 2011;51(2):305-312.
  • 44200Shilov, A. M., Mel’nik, M. V., Voevodina, E. S., Osiia, A. O., and Griaznov, D. A. [Prophylaxis of ischemic heart lesions during chronic heart failure with complex therapy using Q10 coenzyme]. Anesteziol.Reanimatol. 2011;(2):34-38.
  • 44201Spurney, C. F., Rocha, C. T., Henricson, E., Florence, J., Mayhew, J., Gorni, K., Pasquali, L., Pestronk, A., Martin, G. R., Hu, F., Nie, L., Connolly, A. M., and Escolar, D. M. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve 2011;44(2):174-178.
  • 44202Patchett, D. C. and Grover, M. L. Mitochondrial myopathy presenting as rhabdomyolysis. J Am Osteopath.Assoc. 2011;111(6):404-405.
  • 44203Meier, T., Perlman, S. L., Rummey, C., Coppard, N. J., and Lynch, D. R. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012;259(2):284-291.
  • 44204Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., and Chinnery, P. F. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain 2011;134(Pt 9):2677-2686.
  • 44205Tang, K. F., Xing, Y., Wu, C. Y., Liu, R. Z., Wang, X. Y., and Xing, J. P. [Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia]. Zhonghua Nan.Ke.Xue. 2011;17(7):615-618.
  • 44206Traber, G., Baumgartner, M. R., Schwarz, U., Pangalu, A., Donath, M. Y., and Landau, K. Subacute bilateral visual loss in methylmalonic acidemia. J Neuroophthalmol. 2011;31(4):344-346.
  • 44207Mikhin, V. P., Kharchenko, A. V., Rosliakova, E. A., and Cherniatina, M. A. [Application of coenzyme Q(10) in combination therapy of arterial hypertension]. Kardiologiia. 2011;51(6):26-31.
  • 44208Sieswerda, E., van Dalen, E. C., Postma, A., Cheuk, D. K., Caron, H. N., and Kremer, L. C. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst.Rev. 2011;(9):CD008011.
  • 44209Simonenko, V. B., Stepaniants, O. S., and Teslia, A. N. [Myocardial cytoprotectors, a reserve therapeutic modality for patients with stable angina of effort]. Klin.Med (Mosk) 2011;89(4):34-36.
  • 44210Lee, B. J., Huang, Y. C., Chen, S. J., and Lin, P. T. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 2012;28(3):250-255.
  • 44211Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., and George, P. M. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. Am J Hypertens. 2012;25(2):261-270.
  • 44212Liu, J., Wang, L., Zhan, S. Y., and Xia, Y. Coenzyme Q10 for Parkinson’s disease. Cochrane Database Syst.Rev. 2011;(12):CD008150.
  • 44214Lee, B. J., Huang, Y. C., Chen, S. J., and Lin, P. T. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 2012;28(7-8):767-772.
  • 44215Kearney, M., Orrell, R. W., Fahey, M., and Pandolfo, M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst.Rev. 2012;4:CD007791.
  • 44216Mischley, L. K., Allen, J., and Bradley, R. Coenzyme Q10 deficiency in patients with Parkinson’s disease. J.Neurol.Sci. 7-15-2012;318(1-2):72-75.
  • 44217Hernandez-Ojeda, J., Cardona-Munoz, E. G., Roman-Pintos, L. M., Troyo-Sanroman, R., Ortiz-Lazareno, P. C., Cardenas-Meza, M. A., Pascoe-Gonzalez, S., and Miranda-Diaz, A. G. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J.Diabetes Complications 2012;26(4):352-358.
  • 44218Bookstaver, D. A., Burkhalter, N. A., and Hatzigeorgiou, C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am.J.Cardiol. 8-15-2012;110(4):526-529.
  • 44219Cyrus-Hajmassy, M. [Bilateral visual deterioration in excessive tobacco and alcohol consumption]. Ophthalmologe 2012;109(9):901-906.
  • 44220Mortensen SA, Vadhanavikit S, Muratsu K, Folkers K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12:155-62.
  • 44221Langsjoen, P. H., Folkers, K., Lyson, K., Muratsu, K., Lyson, T., and Langsjoen, P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React. 1990;12(3):163-168.
  • 44222Langsjoen, P. H., Langsjoen, P. H., and Folkers, K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. Int J Tissue React. 1990;12(3):169-171.
  • 44223Manzoli, U., Rossi, E., Littarru, G. P., Frustaci, A., Lippa, S., Oradei, A., and Aureli, V. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React. 1990;12(3):173-178.
  • 44224Armstrong, M. J. and Miyasaki, J. M. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 8-7-2012;79(6):597-603.
  • 44225Larijani, V. N., Ahmadi, N., Zeb, I., Khan, F., Flores, F., and Budoff, M. Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function: the FAITH randomized clinical trial. Nutrition 2013;29(1):71-75.
  • 44226Cordero, M. D., Cotan, D., del-Pozo-Martin, Y., Carrion, A. M., de, Miguel M., Bullon, P., and Sanchez-Alcazar, J. A. Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition 2012;28(11-12):1200-1203.
  • 44227Bloomer, R. J., Canale, R. E., McCarthy, C. G., and Farney, T. M. Impact of oral ubiquinol on blood oxidative stress and exercise performance. Oxid.Med.Cell Longev. 2012;2012:465020.
  • 44228Fogagnolo, P., Sacchi, M., Ceresara, G., Paderni, R., Lapadula, P., Orzalesi, N., and Rossetti, L. The effects of topical coenzyme Q10 and vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate after cataract surgery: a clinical and in vivo confocal study. Ophthalmologica 2013;229(1):26-31.
  • 44229Stacpoole, P. W., DeGrauw, T. J., Feigenbaum, A. S., Hoppel, C., Kerr, D. S., McCandless, S. E., Miles, M. V., Robinson, B. H., and Tang, P. H. Design and implementation of the first randomized controlled trial of coenzyme CoQ(1)(0) in children with primary mitochondrial diseases. Mitochondrion. 2012;12(6):623-629.
  • 44230Kato, T., Yoneda, S., Kako, T., Koketsu, M., Hayano, I., and Fujinami, T. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. Int J Clin Pharmacol Ther.Toxicol 1990;28(3):123-126.
  • 44232Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q(1)(0) supplementation on heart failure: a meta-analysis. Am.J.Clin.Nutr. 2013;97:268-75.
  • 44233Deichmann, R. E., Lavie, C. J., and Dornelles, A. C. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys.Sportsmed. 2012;40(4):88-95.
  • 44234Barboni, P., Valentino, M. L., La, Morgia C., Carbonelli, M., Savini, G., De, Negri A., Simonelli, F., Sadun, F., Caporali, L., Maresca, A., Liguori, R., Baruzzi, A., Zeviani, M., and Carelli, V. Idebenone treatment in patients with OPA1-mutant dominant optic atrophy. Brain 2013;136(Pt 2):e231.
  • 44235Klopstock, T., Metz, G., Yu-Wai-Man, P., Buchner, B., Gallenmuller, C., Bailie, M., Nwali, N., Griffiths, P. G., von, Livonius B., Reznicek, L., Rouleau, J., Coppard, N., Meier, T., and Chinnery, P. F. Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy. Brain 2013;136(Pt 2):e230.
  • 44236Desnuelle, C., Pellissier, J. F., Serratrice, G., Pouget, J., and Turnbull, D. M. [Kearns-Sayre syndrome: mitochondrial encephalomyopathy caused by deficiency of the respiratory chain]. Rev Neurol (Paris) 1989;145(12):842-850.
  • 44237Langsjoen, P. H., Folkers, K., Lyson, K., Muratsu, K., Lyson, T., and Langsjoen, P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr 7-1-1988;66(13):583-590.
  • 44239Bresolin, N., Bet, L., Ferrante, C., Binda, A., Carenzi, A., Moggio, M., Comi, G., and Scarlato, G. Immunological and biochemical studies and pilot therapeutic trial with ubidecarenone in Kearns-Sayre patients. Adv Neurol 1988;48:239-256.
  • 44240Bresolin, N., Bet, L., Binda, A., Moggio, M., Comi, G., Nador, F., Ferrante, C., Carenzi, A., and Scarlato, G. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 1988;38(6):892-899.
  • 44241Ghiringhelli, G. [Therapy with ubidecarenone in various cardiopathies with and without decompensation. Comparison with a standard therapy]. Boll.Chim.Farm. 1986;125(3):28S-33S.
  • 44242Tomono, Y., Hasegawa, J., Seki, T., Motegi, K., and Morishita, N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther.Toxicol 1986;24(10):536-541.
  • 44243Goda, S., Hamada, T., Ishimoto, S., Kobayashi, T., Goto, I., and Kuroiwa, Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol. 1987;234(1):62-63.
  • 44244Folkers, K. and Wolaniuk, A. Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp.Clin Res 1985;11(8):539-545.
  • 44245Oda, T. Effect of coenzyme Q10 on stress-induced cardiac dysfunction in paediatric patients with mitral valve prolapse: a study by stress echocardiography. Drugs Exp.Clin Res 1985;11(8):557-576.
  • 44246Langsjoen PH, Vadhanavikit S, Folkers K. Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drugs Exp.Clin Res 1985;11:577-9.
  • 44247Mortensen, S. A., Vadhanavikit, S., Baandrup, U., and Folkers, K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exp.Clin Res 1985;11(8):581-593.
  • 44249Langsjoen, P. H., Vadhanavikit, S., and Folkers, K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc.Natl.Acad.Sci U.S.A 1985;82(12):4240-4244.
  • 44250Folkers, K., Wolaniuk, J., Simonsen, R., Morishita, M., and Vadhanavikit, S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc.Natl.Acad.Sci U.S.A 1985;82(13):4513-4516.
  • 44251Ogasahara, S., Nishikawa, Y., Yorifuji, S., Soga, F., Nakamura, Y., Takahashi, M., Hashimoto, S., Kono, N., and Tarui, S. Treatment of Kearns-Sayre syndrome with coenzyme Q10. Neurology 1986;36(1):45-53.
  • 44252Ogasahara, S., Yorifuji, S., Nishikawa, Y., Takahashi, M., Wada, K., Hazama, T., Nakamura, Y., Hashimoto, S., Kono, N., and Tarui, S. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology 1985;35(3):372-377.
  • 44253Gini, M., Schiavi, M., and Mazzola, C. [Ubidecarenone (coenzyme Q10) in the therapy of chronic cor pulmonale]. Boll.Chim.Farm. 1985;124(4):21S-28S.
  • 44256Matsumura, T., Saji, S., Nakamura, R., and Folkers, K. Evidence for enhanced treatment of periodontal disease by therapy with coenzyme Q. Int J Vitam.Nutr Res 1973;43(4):537-548.
  • 44257Littarru, G. P., Nakamura, R., Ho, L., Folkers, K., and Kuzell, W. C. Deficiency of coenzyme Q 10 in gingival tissue from patients with periodontal disease. Proc.Natl.Acad.Sci U.S.A 1971;68(10):2332-2335.
  • 44259Okuyama, S. and Mishina, H. Principia of cancer therapy. VI. Application of ubiquinone ointment for intractable radiation ulcers: an expanded cytochrome C effect? Sci Rep.Res Inst.Tohoku Univ [Med] 1983;30(1-4):36-39.
  • 44260Okamura, T., Sunamori, M., Amano, J., Hirooka, Y., Ozeki, M., Tanaka, A., and Suzuki, A. Combined treatment of coenzyme Q10 and aprotinin with intraaortic balloon pumping following aorto-coronary bypass surgery. Jpn.J Surg 1984;14(2):97-103.
  • 44262Tajima, M. [Chronic cardiotoxicity of anthracycline derivatives and possible prevention by coenzyme Q10]. Gan No Rinsho 1984;30(9 Suppl):1211-1216.
  • 44263Oda, T. and Hamamoto, K. Effect of coenzyme Q10 on the stress-induced decrease of cardiac performance in pediatric patients with mitral valve prolapse. Jpn.Circ.J 1984;48(12):1387.
  • 44264Suzuki, H., Naitoh, T., Kuniyoshi, S., Banba, N., Kuroda, H., Suzuki, Y., Hiraiwa, M., Yamazaki, N., Ishikawa, M., Hashigami, Y., and . Cardiac performance and coenzyme Q10 in thyroid disorders. Endocrinol Jpn. 1984;31(6):755-761.
  • 44265Cortes, E. P., Gupta, M., Chou, C., Amin, V. C., and Folkers, K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat.Rep. 1978;62(6):887-891.
  • 44266Okuma, K., Furuta, I., and Ota, K. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin]. Gan To Kagaku Ryoho 1984;11(3):502-508.
  • 44267Tsubaki, K., Horiuchi, A., Kitani, T., Taniguchi, N., Masaoka, T., Shibata, H., Yonezawa, T., Tsubakio, T., Kawagoe, H., Shinohara, Y., and . [Investigation of the preventive effect of CoQ10 against the side- effects of anthracycline antineoplastic agents]. Gan To Kagaku Ryoho 1984;11(7):1420-1427.
  • 44268Tanaka, J., Tominaga, R., Yoshitoshi, M., Matsui, K., Komori, M., Sese, A., Yasui, H., and Tokunaga, K. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann.Thorac.Surg. 1982;33(2):145-151.
  • 44269Takimoto, M., Sakurai, T., Kodama, K., Yokoi, H., Suzuki, Y., Enomoto, K., and Okada, N. [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy]. Gan To Kagaku Ryoho 1982;9(1):116-121.
  • 44270Folkers, K., Drzewoski, J., Richardson, P. C., Ellis, J., Shizukuishi, S., and Baker, L. Bioenergetics in clinical medicine. XVI. Reduction of hypertension in patients by therapy with coenzyme Q10. Res Commun.Chem Pathol.Pharmacol 1981;31(1):129-140.
  • 44271Suzuki, Y., Kadowaki, H., Atsumi, Y., Hosokawa, K., Katagiri, H., Kadowaki, T., Oka, Y., Uyama, K., Mokubo, A., Asahina, T., and . A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation and successful therapy with coenzyme Q10. Endocr.J 1995;42(2):141-145.
  • 44274Tsuyama, Y., Adachi-Usami, E., and Takeda, N. A case of Kearns-Shy syndrome with later onset. Ophthalmologica 1993;206(3):149-151.
  • 44275Kuklinski, B., Weissenbacher, E., and Fahnrich, A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol.Aspects Med 1994;15 Suppl:s143-s147.
  • 44276Oda, T. Recovery of load-induced left ventricular diastolic dysfunction by coenzyme Q10: echocardiographic study. Mol.Aspects Med 1994;15 Suppl:s149-s154.
  • 44277Morisco C, Nappi A, Argenziano L, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol.Aspects Med 1994;15 Suppl:s155-s63.
  • 44278Langsjoen, H., Langsjoen, P., Langsjoen, P., Willis, R., and Folkers, K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol.Aspects Med 1994;15 Suppl:s165-s175.
  • 44279Iarussi, D., Auricchio, U., Agretto, A., Murano, A., Giuliano, M., Casale, F., Indolfi, P., and Iacono, A. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non- Hodgkin lymphoma. Mol.Aspects Med 1994;15 Suppl:s207-s212.
  • 44280Lockwood, K., Moesgaard, S., Hanioka, T., and Folkers, K. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol.Aspects Med 1994;15 Suppl:s231-s240.
  • 44283Weber, C., Jakobsen, T. S., Mortensen, S. A., Paulsen, G., and Holmer, G. Effect of dietary coenzyme Q10 as an antioxidant in human plasma. Mol.Aspects Med 1994;15 Suppl:s97-s102.
  • 44284Ishiyama, T., Morita, Y., Toyama, S., Yamagami, T., and Tsukamoto, N. A clinical study of the effect of coenzyme Q on congestive heart failure. Jpn.Heart J 1976;17(1):32-42.
  • 44285Berio, A. and Piazzi, A. Improvement of Kearns-Sayre syndrome with controlled carbohydrate intake and coenzyme Q10 therapy. Ophthalmologica 1994;208(6):342-343.
  • 44286Yamagami, T., Shibata, N., and Folkers, K. Bioenergetics in clinical medicine. VIII. Adminstration of coenzyme Q10 to patients with essential hypertension. Res Commun.Chem.Pathol.Pharmacol 1976;14(4):721-727.
  • 44287Weber, C., Sejersgard, Jakobsen T., Mortensen, S. A., Paulsen, G., and Holmer, G. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Int J Vitam.Nutr Res 1994;64(4):311-315.
  • 44288Rengo F, Abete P, Landino P, et al. Role of metabolic therapy in cardiovascular disease. Clin Investig. 1993;71(8 Suppl):S124-S8.
  • 44289Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clin Investig. 1993;71(8 Suppl):S129-33.
  • 44290Langsjoen, P. H., Langsjoen, P. H., and Folkers, K. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. Clin Investig. 1993;71(8 Suppl):S140-S144.
  • 44291Baggio, E., Gandini, R., Plancher, A. C., Passeri, M., and Carmosino, G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure (interim analysis). The CoQ10 Drug Surveillance Investigators. Clin Investig. 1993;71(8 Suppl):S145-S149.
  • 44292Judy, W. V., Stogsdill, W. W., and Folkers, K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin Investig. 1993;71(8 Suppl):S155-S161.
  • 44293Fujimoto, S., Kurihara, N., Hirata, K., and Takeda, T. Effects of coenzyme Q10 administration on pulmonary function and exercise performance in patients with chronic lung diseases. Clin Investig. 1993;71(8 Suppl):S162-S166.
  • 44294Chen, Y. F., Lin, Y. T., and Wu, S. C. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. J Thorac.Cardiovasc.Surg. 1994;107(1):242-247.
  • 44296Matthews, P. M., Ford, B., Dandurand, R. J., Eidelman, D. H., O’Connor, D., Sherwin, A., Karpati, G., Andermann, F., and Arnold, D. L. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43(5):884-890.
  • 44297Folkers, K., Morita, M., and McRee, J., Jr. The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochem Biophys.Res Commun. 5-28-1993;193(1):88-92.
  • 44298Porter, D. A., Costill, D. L., Zachwieja, J. J., Krzeminski, K., Fink, W. J., Wagner, E., and Folkers, K. The effect of oral coenzyme Q10 on the exercise tolerance of middle- aged, untrained men. Int J Sports Med 1995;16(7):421-427.
  • 44299Laaksonen, R., Fogelholm, M., Himberg, J. J., Laakso, J., and Salorinne, Y. Ubiquinone supplementation and exercise capacity in trained young and older men. Eur.J Appl.Physiol Occup.Physiol 1995;72(1-2):95-100.
  • 44300Gold, R., Seibel, P., Reinelt, G., Schindler, R., Landwehr, P., Beck, A., and Reichmann, H. Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. Eur.Neurol. 1996;36(4):191-196.
  • 44302Ranen, N. G., Peyser, C. E., Coyle, J. T., Bylsma, F. W., Sherr, M., Day, L., Folstein, M. F., Brandt, J., Ross, C. A., and Folstein, S. E. A controlled trial of idebenone in Huntington’s disease. Mov Disord. 1996;11(5):549-554.
  • 44303Malm, C., Svensson, M., Sjoberg, B., Ekblom, B., and Sjodin, B. Supplementation with ubiquinone-10 causes cellular damage during intense exercise. Acta Physiol Scand. 1996;157(4):511-512.
  • 44304Ma A, Zhang W, Liu Z. Effect of protection and repair of injury of mitochondrial membrane- phospholipid on prognosis in patients with dilated cardiomyopathy. Blood Press Suppl 1996;3:53-5.
  • 44305Prieme, H., Loft, S., Nyyssonen, K., Salonen, J. T., and Poulsen, H. E. No effect of supplementation with vitamin E, ascorbic acid, or coenzyme Q10 on oxidative DNA damage estimated by 8-oxo-7,8-dihydro-2′- deoxyguanosine excretion in smokers. Am J Clin Nutr 1997;65(2):503-507.
  • 44306Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., and Beal, M. F. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann.Neurol. 1997;41(2):160-165.
  • 44307Lagendijk, J., Ubbink, J. B., Delport, R., Vermaak, W. J., and Human, J. A. Ubiquinol/ubiquinone ratio as marker of oxidative stress in coronary artery disease. Res Commun.Mol Pathol.Pharmacol. 1997;95(1):11-20.
  • 44311Kim, Y., Sawada, Y., Fujiwara, G., Chiba, H., and Nishimura, T. Therapeutic effect of co-enzyme Q10 on idiopathic dilated cardiomyopathy: assessment by iodine-123 labelled 15-(p-iodophenyl)- 3(R,S)-methylpentadecanoic acid myocardial single-photon emission tomography. Eur.J Nucl.Med 1997;24(6):629-634.
  • 44314Oda, T. Recovery of the systolic time intervals by coenzyme Q10 in patients with a load-induced cardiac dysfunction. Mol.Aspects Med 1997;18 Suppl:S153-S158.
  • 44315Suzuki, Y., Taniyama, M., Muramatsu, T., Atsumi, Y., Hosokawa, K., Asahina, T., Shimada, A., Murata, C., and Matsuoka, K. Diabetes mellitus associated with 3243 mitochondrial tRNA(Leu(UUR)) mutation: clinical features and coenzyme Q10 treatment. Mol.Aspects Med 1997;18 Suppl:S181-S188.
  • 44316Strijks, E., Kremer, H. P., and Horstink, M. W. Q10 therapy in patients with idiopathic Parkinson’s disease. Mol.Aspects Med. 1997;18 Suppl:S237-S240.
  • 44317Weber, C., Bysted, A., and Holmer, G. Coenzyme Q10 in the diet–daily intake and relative bioavailability. Mol.Aspects Med 1997;18 Suppl:S251-S254.
  • 44318Ylikoski, T., Piirainen, J., Hanninen, O., and Penttinen, J. The effect of coenzyme Q10 on the exercise performance of cross-country skiers. Mol.Aspects Med 1997;18 Suppl:S283-S290.
  • 44319Mizuno, M., Quistorff, B., Theorell, H., Theorell, M., and Chance, B. Effects of oral supplementation of coenzyme Q10 on 31P-NMR detected skeletal muscle energy metabolism in middle-aged post-polio subjects and normal volunteers. Mol.Aspects Med 1997;18 Suppl:S291-S298.
  • 44320Sinatra, S. T. Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration. Mol.Aspects Med 1997;18 Suppl:S299-S305.
  • 44321Shults, C. W., Haas, R. H., Passov, D., and Beal, M. F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann.Neurol. 1997;42(2):261-264.
  • 44322Barbiroli, B., Frassineti, C., Martinelli, P., Iotti, S., Lodi, R., Cortelli, P., and Montagna, P. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol.Biol (Noisy.-le-grand) 1997;43(5):741-749.
  • 44324Costeff, H., Apter, N., Elpeleg, O. N., Prialnic, M., and Bohles, H. J. Ineffectiveness of oral coenzyme Q10 supplementation in 3- methylglutaconic aciduria, type 3. Brain Dev. 1998;20(1):33-35.
  • 44325Chopra, R. K., Goldman, R., Sinatra, S. T., and Bhagavan, H. N. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam.Nutr Res 1998;68(2):109-113.
  • 44327Palomaki, A., Malminiemi, K., Solakivi, T., and Malminiemi, O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998;39(7):1430-1437.
  • 44329Kaikkonen, J., Kosonen, L., Nyyssonen, K., Porkkala-Sarataho, E., Salonen, R., Korpela, H., and Salonen, J. T. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic.Res 1998;29(1):85-92.
  • 44330Singh, R. B., Wander, G. S., Rastogi, A., Shukla, P. K., Mittal, A., Sharma, J. P., Mehrotra, S. K., Kapoor, R., and Chopra, R. K. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc.Drugs Ther. 1998;12(4):347-353.
  • 44332Folkers K. Critique of coenzyme Q in biochemical and biomedical research and in ten years of clinical research on cardiovascular disease. J Mol Med 2002;2:431-460.
  • 44333Pogessi L, Galanti G, Corneglio M, and et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. Curr Ther Res 1991;49 :878-886.
  • 44334Mortensen SA, Kumar A, Dolliner P, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure 2013;15:S1-20.
  • 44335Yikoski T, Piirainen J, Hanninen O, and et al. The effect of coenzyme Q10 on the exercise performance of cross-country skiers. Molec Aspects Med 1997;18 Suppl:s283-s290.
  • 44336Mazzola C, Guffanti EE, Vaccarella A, and et al. Noninvasive assessment of coenzyme Q10 in patients with chronic stable effort angina and moderate heart failure. Current Therapeutic Research 1987;41(6):923-932.
  • 44337Schardt F, Welzel D, Scheiss W, and et al. Effect of coenzyme Q10 on ischemia-induced ST-segment depression: a double-blind, placebo-controlled, crossover study. In: Folkers, K and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1985.
  • 44338Roberts J. The effects of coenzyme Q10 on excercise performance. Med Sci Sports Exerc 1990;22((suppl)):S87.
  • 44339Judy WV, Folkers K, and Hall JH. Improved long-term survival in conezyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru GP, and Yamagami T. Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier Science Publishers;1991.
  • 44340Judy, W. V., Hall, J. H., Toth, P. D., and Folkers, K. Double blind double cross over study of coenzyme Q10 in heart failure. In: Folkers, K. and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1986.
  • 44341Langsjoen PH. Treatment of patients with human immunodeficiency virus infection with coenzyme Q10. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1991.
  • 44342Yamagami T, Takagi M, Akagami H, and et al. Effect of coenzyme Q10 on essential hypertension: a double-blind controlled study. In: Folkers K and Yamamura Y. Biomedical and Clinical Aspects on Coenzyme Q. Amsterdam: Elsevier;1986.
  • 44343Digiesi V, Cantini F, and Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Current Therapeutic Research 1990;47(5):841-845.
  • 44344Balercia G, Arnaldi G, Lucarelli G, and et al. Effects of exogenous CoQ10 administration in patients with idiopathic asthenozoospermia. International Journal of Andrology 2000;Suppl 23:43.
  • 44345Kelly P, Vasu S Getato M McNurlan M Lawson WE. Coenzyme Q10 improves myopathic pain in statin treated patients (abstr). J Am Coll Cardiol 2005;45:3A.
  • 44346Young JM, Florkowski CM Molyneux SL McEwan RG Frampton CM George PM. Coenzyme Q10 does not improve simvastatin tolerability in dyslipidemic patients with prior statin-induced myalgia. Circulation 2007;114:II41.
  • 44347Singh RB, Khanna HK, and Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role. J Nutr Environ Med 2000;10:281-288.
  • 44348van Gaal L, Folkers K and Yamamura Y. Exploratory study of coenzyme Q10 in obesity. In: Folkers K and Yamura Y. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier Science Publications;1984.
  • 44349Oda T. Coenzyme Q10 therapy on the cardiac dysfunction in patients with mitral valve prolapse: dose vs effect and dose vs serum level of coenzyme Q10. In: Folkers K and Yamamura Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier Science;1986.
  • 44351Mari D, Alleva R, Tomasetti M, and et al. Reduction of chemotoxicity and enhancement of antioxidant capacity of plasma in cancer patients treated with conventional therapy plus CoQ10. First Conference of the International Coenzyme Q10 Association 2002;
  • 44352Serra G, Lissoni F, Piemonti C, et al. Evaluation of coenzyme Q10 in patients with moderate heart failure and chronic stable effort angina. In: Folkers K, Littaru GP, and Yamagami T. Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier Science Publishers;1991.
  • 44353Teerlink T, Musch EE, Baker SJL, and et al. Resistance of low density lipoprotein against in vitro oxidation is associated with its coenzyme Q10 content in type 2 diabetes. First Conference of the International Coenzyme Q10 Association 2002;
  • 44358Digiesi V, Cantini F, Bisi G, and et al. Mechanism of action of coenzyme Q10 in essential hypertension. Current Therapeutic Research 1992;51(5):668-672.
  • 44359Weber C, Bysted A, and Holmer G. Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects. Nutrition Research 1997;17(6):941-945.
  • 44360Wahlqvist ML, Wattanapenpaiboon N, Savige GS, and et al. Bioavailability of two different formulations of coenzyme Q10 in healthy subjects. Asia Pac J Clin Nutr 1998;7(1):37-40.
  • 44364Schneeberger, W., Muller-Steinwachs, J., Anda, L. P., Fuchs, W., Zilliken, F., Lyson, K., Muratsu, K., and Folkers, K. A clinical double-blind and crossover trial with coenzyme Q10 on patients with cardiac disease. In: Folkers, K. and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier;1986.
  • 44365Ursini T. Coenzyme Q10 treatment of heart failure in the elderly: preliminary results. In: Folkers K, Littarru GP and Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier;1991.
  • 44366Muller-Steinwachs, J, Anda, LP, and Zilliken, F. Eine klinische Doppel-blind-studie mit CoQ10 und vitamin E bei hertzkranken patienten. De Orthomoleculaire Koerier 1990;5(24):4-11.
  • 44367Syrkin A, Kogan A, Drynitsina S, and et al. The effect of soluble form of coenzyme Q10 on the oxygen free radical processes and clinical course in patients with coronary heart disease – stable angina pectoris. First Conference of the International Coenzyme Q10 Association 2002;
  • 44368Beyer RE, Nordenbrand K, and Ernster L. The function of coenzyme Q in free radical production and as an antioxidant: a review. Chemica Scripta 1987;27:145-153.
  • 44369Weber M, Andler W, Enzmann F, and et al. Increased oxidative stress in glycogen storage disease type IB: preliminary results of an antioxidative treatment with coenzyme Q10, selenium and ascorbic acid. First Conference of the International Coenzyme Q10 Association 2002;
  • 44370Centre for Reviews and Dissemination. Idebenone (SNT-MC17) for Friedreich’s ataxia: horizon scanning technology briefing (Project record). 2013;
  • 44371Imanaka K, Izumiyama K, and Sakaguchi T et al. Effect of coenzyme Q10 and azelastin on protecting radiation pneumonitis with lung cancer. Journal of Japan Society for Cancer Therapy 1994;29:2010-2015.
  • 44372Wander GS, Singh RB, and Shukla PK. Randomized double blind trial of hydrosoluble coenzyme Q10 in hypertensives with oxidative stress and coronary artery disease. First Conference of the International Coenzyme Q10 Association 2002;
  • 44373Wyss V, Lubich T Ganzit GP Cesaretti D Fiorella PL Dei C Rocini C Bargossi AM Battistoni R Lippi A Grossi G Sprovieri G Battino M. Remarks on prolonged ubiquinone administration in physical exercise. Highlights in Ubiquinone Research 1990;303-308.
  • 44374Zeppilli P, Merlino B De Luca A Palmieri V Santini C Vannicelli R La Rosa Gangi M Cacese R Cameli S Servidei S Ricci E Silvestri G Lippa S Oradei A Littarru GP. Influence of coenzyme Q10 on physical work capacity in athletes, sedentary people and patients with mitochondrial disease. Biochemical and clinical aspects of Coenzyme Q10. 1991;6
  • 44375Amadio E, Palermo R Peloni G Littarru G. Effect of CoQ10 administration on V02max and diastolic function in athletes. Biomedical and clinical aspects of Coenzyme Q10. 1991;525-533.
  • 44376Fiorella PL, Bargossi AM Grossi G Motta R Senaldi R Battino M Sassi S Sprovieri G Lubich T. Metabolic effects of coenzyme Q10 treatment in high level athletes. Biomedical and clinical aspects of Coenzyme Q10 1991;513-520.
  • 44377Wilkinson EG, Arnold RM, Folkers K, and et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Research Communications in Chemical Pathology and Pharmacology 1975;12(1):111-124.
  • 44378Scaglione F, Lundstrom B, Barbieri B, and et al. Coenzyme Q10 as an immunoenhancer. A single blind placebo-controlled and randomized clinical study [abstract]. First Conference of the International Coenzyme Q10 Association 1998;
  • 44379Gvozdjakova A, Kucharska J, Lepies P, and et al. Decreased level of sperm coenzyme Q10, mitochondrial respiration and energy production in infertile patients therapeutic effect on coenzyme Q10 (a pilot study). First Conference of the International Coenzyme Q10 Association 2002;
  • 44380Servidei S, Spinazzola A, Crociani P, and et al. Replacement therapy is effective in familial mitochondrial encephalomyopathy with muscle coenzyme Q10 deficiency. Neurology 1996;46:A420.
  • 44381Bresolin N, Cossutta E, Angelini C, and et al. Fifty patients with mitochondrial myopathy treated with ubidecarenone. First multicentric study. J Neurology 1988;235:S79.
  • 44382Oda T. Effect of coenzyme Q10 on load-induced cardiac dysfunction: double blind study and investigation of dose-response relationship. In: Lenaz G, Barnabei O Rabbi A and et al. Highlights in Ubiquinone Research. London: Taylor and Francis;1990.
  • 44383Oda T. Dose-effect relationship and critical dose of coenzyme Q10 on load-induced cardiac dysfunction in pediatric patients with mitral valve prolapse. In: Folkers K, Littarru GP and Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier Science;1991.
  • 44384Judy WV, Willis RA, and Folkers K. Regression of prostate cancer and plasma specific antigens (PSA) in patients on treatment with COQ10. First Conference of the International Coenzyme Q10 Association 2002;
  • 44385Aoki S and Yamaguchi K. [Clinical experiences in use of cinnarizine and CoQ10 for treatment of sensorineural tinnitus]. Shinyaku to Rinsho 1970;29:1541-1546.
  • 44386Rastogi SS, Singh RB, and Shukla PK. Randomized, double blind, placebo controlled trial of hydrosoluble coenzyme Q10 in patients with hyperinsulinemia. First Conference of the International Coenzyme Q10 Association 2002;
  • 44387Gvozdjakova A, Kucharska J, Braunova Z, and et al. Beneficial effect of CoQ10 on the antioxidative status and metabolism of fats and sugars in diabetic patients. First Conference of the International Coenzyme Q10 Association 2002;
  • 44388Koroshetz WJ. Care-HD: NINDS multicenter trial in Huntington’s disease to test whether specific doses of coenzyme Q10 and remacemide slow disease progression. First Conference of the International Coenzyme Q10 Association 2002;
  • 44389Feigin A, Kieburtz K, Como P, and et al. An open-label trial of coenzyme Q10 (CoQ) in Huntington’s disease (HD) [abstract]. Neurology 1994;44(suppl 2):A397-A398.
  • 89413Folkers K. Survey on the vitamin aspects of coenzyme Q. Int Z Vitaminforsch. 1969;39(3):334-52.
  • 89416Cordero MD, Alcocer-Gómez E, de Miguel M, et al. Can coenzyme Q10 improve clinical and molecular parameters in fibromyalgia? Antioxid Redox Signal. 2013;19(12):1356-61.
  • 89417Emmanuele V, López LC, Berardo A, et al. Heterogeneity of coenzyme Q10 deficiency. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol. 2012;69(8):978-83.
  • 89419Gvozdjáková A, Kucharská J, Ostatníková D, et al. Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longev. 2014;2014:798957.
  • 89420Lesser GJ, Case D, Stark N, et al; Wake Forest University Community Clinical Oncology Program Research Base. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013;11(1):31-42.
  • 89421Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-52.
  • 89422Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. J Urol. 2012;188(2):526-31.
  • 89423Safarinejad MR, Shafiei N, Safarinejad S. Effects of EPA, ?-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial. Br J Nutr. 2013;110(1):164-71.
  • 90427Chen C, Zhou X-Z, Fan Y-M, et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment 2008;15(19):1503-5, 510.
  • 92904Alehagen U, Johansson P, Bjornstedt M, et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 2013;167(5):1860-6.
  • 92908Bogsrud MP, Langslet G, Ose L, et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scand Cardiovasc J 2013;47(2):80-7.
  • 92909Fedacko J, Pella D, Fedackova P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol 2013;91(2):165-70.
  • 95602Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015 Jan;90(1):24-34. doi: 10.1016/j.mayocp.2014.08.021.
  • 95603Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015 Feb;238(2):329-35. doi: 10.1016/j.atherosclerosis.2014.12.016. Epub 2014 Dec 17.
  • 95604Skarlovnik A, Janic M, Lunder M, Turk M, Sabovic M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit. 2014 Nov 6;20:2183-8. doi: 10.12659/MSM.890777.
  • 95605Wang LW, Jabbour A, Hayward CS, Furlong TJ, Girgis L, Macdonald PS, et al. Potential role of coenzyme Q10 in facilitating recovery from statin-induced rhabdomyolysis. Intern Med J. 2015 Apr;45(4):451-3. doi: 10.1111/imj.12712.
  • 95606Forester BP, Harper DG, Georgakas J, Ravichandran C, Madurai N, Cohen BM. Antidepressant effects of open label treatment with coenzyme Q10 in geriatric bipolar depression.J Clin Psychopharmacol. 2015 Jun;35(3):338-40. doi: 10.1097/JCP.0000000000000326.
  • 95607Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2016 Mar 3;3:CD007435. doi: 10.1002/14651858.CD007435.pub3.
  • 95608Shoeibi A, Olfati N, Soltani Sabi M, Salehi M, Mali S, Akbari Oryani M. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg. 2017 Mar;117(1):103-109. doi: 10.1007/s13760-016-0697-z.
  • 95609Zhao Q, Kebbati AH, Zhang Y, Tang Y, Okello E, Huang C. Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. J Investig Med. 2015 Jun;63(5):735-9. doi: 10.1097/JIM.0000000000000202.
  • 95610Zhu ZG, Sun MX, Zhang WL, Wang WW, Jin YM, Xie CL. The efficacy and safety of coenzyme Q10 in Parkinson’s disease: a meta-analysis of randomized controlled trials. Neurol Sci 2017;38(2):215-224.
  • 95707Claessens AJ, Yeung CK, Risler LJ, Phillips BR, Himmelfarb J, Shen DD. Rapid and sensitive analysis of reduced and oxidized coenzyme Q10 in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and application to studies in healthy human subjects. Ann Clin Biochem. 2016;53(Pt 2):265-73.
  • 95755LaValle JB. Hidden disruptions in metabolic syndrome: drug-induced nutrient depletion as a pathway to accelerated pathophysiology of metabolic syndrome. Altern Ther Health Med. 2006 Mar-Apr;12(2):26-31; quiz 32-3.
  • 95756Garrido-Maraver J, Cordero MD, Oropesa-Ávila M, et al. Coenzyme Q10 therapy. Mol Syndromol. 2014;5(3-4):187-97.
  • 96531Guilbot A, Bangratz M, Ait Abdellah S, Lucas C. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study. BMC Complement Altern Med. 2017;17(1):433. doi: 10.1186/s12906-017-1933-7.
  • 96537Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, et al. The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson’s disease. Eur Neurol. 2015;73(3-4):205-11. doi: 10.1159/000377676.
  • 96538McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K,et al; Huntington Study Group 2CARE Investigators and Coordinators. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88(2):152-159. doi: 10.1212/WNL.0000000000003478.
  • 96539Sanoobar M, Dehghan P, Khalili M, Azimi A, Seifar F. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial. Nutr Neurosci. 2016;19(3):138-43. doi: 10.1179/1476830515Y.0000000002.
  • 96540Donnino MW, Mortensen SJ, Andersen LW, Chase M, Berg KM, Balkema J, et al. Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial. Crit Care. 2015;19:275. doi: 10.1186/s13054-015-0989-3.
  • 96541Tabrizi R, Akbari M, Sharifi N, Lankarani KB, Moosazadeh M, Kolahdooz F, et al. The effects of coenzyme Q10 supplementation on blood pressures among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev. 2018;25(1):41-50. doi: 10.1007/s40292-018-0247-2.
  • 96542Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D,et al; Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-9.
  • 96543Aslanabadi N, Safaie N, Asgharzadeh Y, Houshmand F, Ghaffari S, Garjani A, et al. The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention. Cardiovasc Ther. 2016;34(4):254-60. doi: 10.1111/1755-5922.12195.
  • 96544Moradi M, Haghighatdoost F, Feizi A, Larijani B, Azadbakht L. Effect of coenzyme Q10 supplementation on diabetes biomarkers: a systematic review and meta-analysis of randomized controlled clinical trials. Arch Iran Med. 2016;19(8):588-96. doi: 0161908/AIM.0012.
  • 96545Sahebkar A, Simental-Mendía LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res. 2016;105:198-209. doi: 10.1016/j.phrs.2016.01.030.
  • 96546Alehagen U, Aaseth J, Johansson P. Reduced cardiovascular mortality 10 years after supplementation with selenium and coenzymeQ10 for four years: follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly citizens. PLoS One. 2015;10(12):e0141641.
  • 96547Zhang P, Yang C, Guo H, Wang J, Lin S, Li H, et al. Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals. J Clin Lipidol. 2018;12: 417-427. doi: 10.1016/j.jacl.2017.12.006.
  • 96548Tan JT, Barry AR. Coenzyme Q10 supplementation in the management of statin-associated myalgia. Am J Health Syst Pharm. 2017;74(11):788-93.15. doi: 10.2146/ajhp160714.
  • 97466Alehagen U, Aaseth J, Alexander J, Johansson P. Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly. PLoS One. 2018 Apr 11;13(4):e0193120.
  • 97902Lei L, Liu Y. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. BMC Cardiovasc Disor. 2017 Jul 24;17(1):196.
  • 97903Rivara MB, Yeung CK, Robinson-Cohen C, et al. Effect of coenzyme Q10 on biomarkers of oxidative stress and cardiac function in hemodialysis patients: the CoQ10 biomarker trial. Am J Kidney Dis. 2017 Mar;69(3):389-99.
  • 97904Gumus K. Topical coenzyme Q10 eye drops as an adjuvant treatment in challenging refractory corneal ulcers: a case series and literature review. Eye Contact Lens. 2017 Mar;43(2):73-80.
  • 97905Kim J, Medsinge A, Chauhan B, et al. Coenzyme Q10 in the treatment of corneal edema in Kearns-Sayre: is there an application in Fuchs endothelial corneal dystrophy? Cornea. 2016 Sep;35(9):1250-4.
  • 97906Alehagen U, Alexander J, Aaseth J. Supplementation with selenium and coenzyme Q10 reduces cardiovascular mortality in elderly with low selenium status. A secondary analysis of a randomized clinical trial. PLoS One. 2016 Jul 1;11(7):e0157541.
  • 97907Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA. Functions of coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr. 2016 May-Jun;35(4):346-53.
  • 97908Iwase S, Kawaguchi T, Yotsumoto D, et al. Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). Support Care Cancer. 2016 Feb;24(2):637-46.
  • 97909Postorino El, Rania L, Aragona E, et al. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol. 2018 Jan;28(1):25-31.
  • 97910Toth S, Sajty M, Pekarova T, et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combine dyslipidemia. J Basic Clin Physiol Pharmacol. 2017 Jul 26;28(4):327-336.
  • 97911Stojanovic M, Radenkovic M. A meta-analysis of randomized and placebo-controlled clinical trials suggests that coenzyme Q10 at low dose improves glucose and HbA1c levels. Nutr Res. 2017 Feb;38:1-12.
  • 97912Alcocer-Gomez E, Culic O, Navarro-Pando JM, Sanchez-Alcazar JA, Bullon P. Effect of coenzyme Q10 on psychopathological symptoms in fibromyalgia patients. CNS Neurosci Ther. 2017 Feb;23(2):188-189.
  • 97913Di Pierro F, Rossi A, Consensi A, Giacomelli C, Bazzichi L. Role for a water-soluble form of CoQ10 in female subjects affected by fibromyalgia. A preliminary study. Clin Exp Rhuematol. 2017 May-Jun;35 Suppl 105(3):20-27.
  • 97914Samimi M, Zarezade Mehrizi M, Foroozanfard F, et al. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2017 Apr;86(4):560-66.
  • 97916Shao L, Ma A, Figtree G, Zhang P. Combination therapy with coenzyme Q10 and trimetazidine in patients with acute viral myocarditis. J Cardiovasc Pharmacol. 2016 Aug;68(2):150-4.
  • 97917Peel MM, Cooke M, Lewis-Peel HJ, Lea RA, Moyle W. A randomized controlled trial of coenzyme Q10 for fatigue in the late-onset sequelae of poliomyelitis. Complement Ther Med. 2015 Dec;23(6):789-93.
  • 97918Suksomboon N, Poolsup N, Juanak N. Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis. J Clin Pharm Ther. 2015 Aug;40(4):413-8.
  • 99427Chen FL, Chang PS, Lin YC, Lin PT. A Pilot Clinical Study of Liquid Ubiquinol Supplementation on Cardiac Function in Pediatric Dilated Cardiomyopathy. Nutrients 2018;10(11). pii: E1697. doi: 10.3390/nu10111697.
  • 99429Orlando P, Silvestri S, Galeazzi R, et al. Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes. Redox Rep 2018;23(1):136-45. doi: 10.1080/13510002.2018.1472924.
  • 99430Zeng Z, Li Y, Lu S, Huang W, Di W. Efficacy of CoQ10 as supplementation for migraine: A meta-analysis. Acta Neurol Scand 2019;139(3):284-93. doi: 10.1111/ane.13051.
  • 99636Fallah M, Askari G, Soleimani A, Feizi A, Asemi Z. Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients. Int Urol Nephrol 2018;50(11):2073-9. doi: 10.1007/s11255-018-1973-z.
Vind een orthomoleculaire therapeut bij jou in de buurt
Sluiten